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I. Abstract 
Afadin (AF6) is a scaffolding protein involved in the formation of protein complexes at 
tight and adherens junctions. AF6 plays vital roles in many cellular processes, such as structural 
development, cellular organization, directional cell movement, and polarity. The PDZ domain 
participates in multiple signaling networks to initiate and maintain cellular polarity, to facilitate 
protein trafficking, and allow neuronal communications; thus, misregulated PDZ domain-
dependent pathways can induce cells to become cancerous. AF6 interacts with many other 
proteins via its PDZ signaling domain and exhibits multimodal specificity. 
The PDZ signaling domain of AF6 (AF6_PDZ) binds predominantly hydrophobic 
peptide ligands. A biological array binding study has shown that AF6_PDZ can also recognize 
peptide ligands that contain diverse features compared to those of cognate sequence. The 
plasticity of the AF6_PDZ to recognize chemically diverse ligands raises questions regarding 
how AF6_PDZ achieves specificity in peptide recognition, as well as which binding pocket 
interactions are important for peptide binding.  
Structures of the AF6_PDZ with several biological peptide ligands highlight 
intermolecular interactions that stabilize these ligands at the binding pocket. We hypothesize 
that these interactions play a key role in recruiting the ligand to a “hot spot” on the AF6_PDZ 
surface and promote binding. This hypothesis predicts that changing the interactions by 
introducing mutations into the peptide sequence will alter the peptide binding affinity. The 
protein-peptide interactions in this project were studied predominantly with 1H-15N-
heteronuclear single quantum coherence nuclear magnetic resonance (HSQC NMR) titration.  
We selected two non-cognate peptides suspected of binding to AF6_PDZ but found 
that these peptides only weakly interact with AF6_PDZ. Based on this result, we suggest that 
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AF6_PDZ cannot recognize peptide with a deviated residue at the extreme C-terminal 
position of the peptide (P0). In specific, an arginine or a proline amino acid is likely not 
preferable residue at this position of the peptide. Using knowledge-based approach, we 
introduced a valine at the P0 of the peptide, successfully restoring binding. This result 
highlights the crucial role of the valine in promote binding. The disassociation constants KD 
for binding interaction of AF6_PDZ with cognate peptide (Class I ligand) and designed 
peptide (Class II ligand) are 154 µM and 26.4 µM respectively, and these values are 
consistent with what others have observed previously. We also studied shifted motif ligands, 
in which we investigated whether AF6_PDZ can accommodate ligands with an additional C-
terminal residue to the P0 valine. We conclude that the AF6_PDZ does not have the ability to 
recognize these peptides, and the shifted motif binding mode is likely not relevant for 
AF6_PDZ in biological environment. Comparison of available structures reveals the 
possibility that αA helix of AF6_PDZ may impose some structural constraint, and thereby 
inhibit the protein recognition of shifted motif peptides. We also suggest that the list of the top 
100 binding sequences from the peptide screening experiment does not reflect all biological 
binders; thus, this list needs to be used with precaution in future experiments. Altogether, we 
confirm the important interactions that the valine at P0 forms at the binding pocket and these 
interactions help targeting the peptide to the binding pocket to promote binding. This finding 
will aid scientists in designing therapeutic drugs that targets the AF6_PDZ, in specific, and 
PDZ-domain containing proteins, in generally.   
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II. Introduction 
Important roles of afadin (AF6) protein 
Protein-protein interactions play a crucial role in organizing the scaffolding proteins that 
are the centerpiece of signaling networks. Scaffolding proteins serve as the framework where 
signaling complexes are built to induce differential downstream effects.1 Afadin (AF6) is a well-
known scaffolding protein that participates in the formation of both tight junction (TJ) and 
adherens junction (AJ) complexes (Figure 1A).2,3 These complexes have different compositions 
and functions in epithelial cells. AJs initiate and maintain cell-cell contact during the maturation 
of cells, and thereby regulate the process of tissue organization and morphogenesis; while TJs 
coordinate solute and ion movements between cells.4-7 AF6 serves as a connector as it binds actin 
filament (F-actin) and the cytosolic domain of nectin.3,8 It further interacts with non-receptor 
tyrosine kinase c-Src, and a subset of G protein such as Rap1 and Rac to restructure the actin 
cytoskeleton.9 Consequently, AF6 recruits the cadherin-catenin system, and junctional adhesion 
molecule (JAM) and claudin to form AJ and TJ complexes respectively.9 These interactions 
emphasize the crucial role of AF6 in establishing cellular polarity and integrity.  
AF6 also regulates cell mobility. Cytosolic AF6 can be recruited to the leading edge of a 
cell, together with tyrosine phosphatase SHP-2.10 The AF6-SHP-2 complex regulates the 
activation of the platelet-derived growth factor (PDGF) receptor and its downstream effectors to 
facilitate a directional cell movement (Figure 1B).10 Furthermore, in mouse development studies, 
AF6 has been found to be a crucial regulator of the processes of structural development and 
organization in the embryo, in which the absence of AF6 leads to the defective epithelial polarity 
and embryonic death.11,12 Later research reveals that AF6 plays an important role in spindle 
orientation and regulating planar cell division during embryonic development.13 These 
6 
 
observations highlight the importance of AF6 in the early phases of embryonic development. 
Lastly, AF6 has been identified as a regulator of cellular growth processes upon its relocalization 
to the nucleus.14 AF6 can be phosphorylated by Akt kinase, and phosphorylated AF6 undergoes 
translocation from the cell junction to the nucleus, which in turn upregulates cell migration 
(Figure 1C).15 Altogether, AF6 is a crucial component in establishing cellular junctions and 
polarity, facilitating directional cell movement, and regulating cellular growth processes.  
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Figure 1: Schematic representation of various pathways that involve with AF6. (A) AF6 
participates in the formation of AJ and TJ complexes. (B) AF6 recruits SHP-2 and helps 
facilitate directional movement of the cell. (C) Relocalization of AF6 to the nucleus upon 
phosphorylation by Akt regulates other cellular growth processes, cell migration, and 
proliferation. 
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Structure of AF6 protein 
Human AF6 is a large protein (207 kDa)16 that contains two Ras-association domains 
(RA), a forkhead-associated domain (FHA), a dilute domain motif (DIL), a Postsynaptic density-
95/Disc large/Zonula occludens-1 (PDZ) domain, and three proline-rich (PR) regions (Figure 
2).17-18 Its RA domains interact with a subfamily of Ras, and tight junction protein ZO-1.20-22 The 
FHA domain binds phosphopeptides.23 The PR regions recognize many other molecular 
recognition domains including Src homolog 3 (SH3) domains, Drosophila enabled/vasodilator-
stimulated phosphoprotein homology 1 (EVH1) domains, WW domains, GYF domains, and 
ubiquitin E2 variant (UEV) domains.24-28 AF6 is known to interact with many proteins via its 
PDZ domain such as junctional adhesion molecule (JAM)29, ephrin (Eph) receptor tyrosine 
kinases (RTKs) 22,30, nectin/poliovirus receptor-related protein (PRR)8, breakpoint cluster region 
protein (Bcr)31, Notch ligand Jagged-132, neurexin34, and c-Src35. These non-catalytical domains 
illustrate the role of AF6 as a scaffolding protein, due to their ability to recruit various signaling 
domains and thereby allow AF6 to participate in many signal transduction pathways.  
 
Figure 2: Schematic representation of human AF6 protein. AF6 contains two FA domains, a FHA 
domain, a DIL domain, and a PDZ domain. 
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Biological roles and structure of PDZ domains  
PDZ domains are widely utilized to affect signaling pathways, and are one of the most 
numerous domains present in the human genome.35 Previous research has identified 364 PDZ-
containing proteins in humans, and many of these protein have several PDZ domains.35 A PDZ 
domain is a motif that has 80 to 100 residues folded into a globular structure with six β-strands 
and two α-helices.36,37 The PDZ domain interacts with its ligands by recognizing the linear 
peptide strand at the C-terminus of its physiological protein partners.35 This is achieved through 
beta-augmentation, where the C-terminal stretch of the peptide ligand forms an antiparallel β-
strand between the second β-strand (βB) and second α-helix (αB) of the PDZ domain (Figure 
3).36 The position of the C-terminal residue of the ligand is defined as position 0 (P0). The 
preceding amino acid is then counted as position -1, and so on. 
 
 
Figure 3: Ribbon representation of the crystal structure of a PDZ domain with a peptide bound.38 
The bound peptide is depicted here in green, with P0 corresponding to the position of the most C-
terminal residue. 
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A PDZ-containing protein employs the peptide recognition module to carry out its 
function as a scaffolding protein to connect complex signaling pathways.39 Many of these 
proteins are found at the postsynaptic density located at neuromuscular junctions and synapses, 
such as the MAGUK and GRIP protein.39 They function as adaptors, and their localization helps 
establish and maintain structures at the junctions to respond to incoming signals.39 PDZ- 
containing proteins also participate in regulating the activity of membrane proteins. For instance, 
the PDZ domain of Na+/H+ exchanger regulatory factor (NHERF) binds to Na+/H+ antiporter 
(NHE3) and interacts with protein kinase A (PKA) to downregulate the activity of NH3.39-41 On 
the other hand, when needed, the PDZ domain of NHERF can also bind to the β2 adrenergic 
receptor to activate NH3.39 This observation highlights the ability of the PDZ domain to 
recognize the C-terminal sequences of various partners, thereby differentially up- or down-
regulating pathways depending on cellular needs.  
The ability of PDZ domains to recognize peptides has been utilized not only by 
physiological partners but also by many viruses. Once a host cell is infected, viral proteins 
interact with various host proteins in a PDZ domain-dependent manner to provide the optimal 
condition for viruses to replicate and divide.42 Human adenovirus E4-ORF1 oncoprotein is 
recognized by human Disks large homolog 1 (Dlg1) protein43 and other PDZ-domain proteins42.  
As a consequence, these interactions disrupt TJ formation and cellular polarity development, and 
activate PI3K signaling cascade to allows cells to become immortal and cancerous.44,45 An 
additional example is rabies viruses, which are categorized into two subgroups, depending on 
their targeted PDZ proteins.46 While one group has a mechanism to attack host cells, the other 
group triggers immune response and causes neuronal cell death.42 These misregulated PDZ 
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domain pathways elucidate the importance of PDZ domains and the vital role of the interactions 
between PDZ domains and their physiological partners. 
 
PDZ domain of AF6 (AF6_PDZ) 
AF6_PDZ interacts with cytosolic domain of various transmembrane proteins such as 
JAM29, some RTKs22,30, nectin8, Jagged-132, and neurexin33. It also binds cytosolic domain of c-
Src34, and cytosolic proteins (Bcr).31 These interactions allow AF6 to participate in various 
signaling pathways inside the cell. AF6_PDZ binds to a subset of RTKs and JAM to recruit itself 
to the cell-cell contact site and be involved in the formation of TJ complexes.29,30 Additionally, 
as a result of binding proteins such as nectin, and c-Src, AF6 plays an important role in the 
formation of AJ and TJ complexes, thereby regulating cellular polarity and integrity (Figure 
1A).9 AF6 can also be phosphorylated by Bcr, consequently undergoing a conformational change 
which allows AF6_PDZ to bind Bcr.31 This interaction downregulates the Ras-mediated 
signaling pathway, thus hindering cell proliferation, survival, and differentiation (Figure 4).31 
 
 
Figure 4: Interaction of AF6 with Bcr. Bcr phosphorylates AF6 and induces conformational 
change of AF6. Upon the conformational change, AF6_PDZ binds Bcr, and hinders cell 
proliferation, differentiation, and survival. 
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PDZ domain classification 
PDZ domains have been divided into three main classes based on the nature of the first 
residue of its αB helix (αB:1) (Figure 5, Table 1A). These differences modulate the nature of the 
ligand to be bound, due to the interaction of this αB:1 residue with the amino acid in the third 
position upstream of the C-terminal residue of the ligand (P-2). Class I PDZ domains have a 
conserved histidine at αB:1, which enables them to form a hydrogen bond with a serine or 
threonine residue at P-2 of the ligand; thus a Class I PDZ domain recognizes ligands with the 
motif (x-S/T-x-Φ-COOH), where x can be any residues and Φ denotes hydrophobic amino 
acids.47-49 Class II PDZ domains recognize ligands with the motif (x-Φ-x-Φ-COOH), due to the 
favorable hydrophobic interaction between residues at αB:1 and P-2, while Class III PDZ 
domains are classified based on the formation of a hydrogen bond between tyrosine at αB:1and 
acidic residues at P-2 of the ligand (x-D/E-x- Φ-COOH).48-51  
 
 
Figure 5: Interaction between αB:1 residue of various PDZ domains and residue at P-2 of its 
ligands. (A) Class I PDZ domain (Protein Data Bank (PDB): 2PDZ53). (B) Class II PDZ domain 
(PDB: 2EJY49). (C) Class III PDZ domain (PDB: 1B8Q51). Nitrogen atoms are shown in blue, 
and oxygen atoms in red, and hydrogen bonds are indicated by dashed lines. The origins of PDZ-
containing proteins and peptides are listed in Table 1. 
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Table 1: PDZ domain classification. (A) PDZ domain classification and representative PDZ-
containing proteins with the sequence that they recognize. X can be any residues and Φ is 
hydrophobic amino acid. Class I: Syntrophin (PDZ domain), voltage-gated sodium channel 
(peptide).53 Class II: Erythrocyte p55 (PDZ domain), glycophorin C (peptide).49 Class III: nNOS 
(PDZ domain), melatonin receptor a (peptide).51 (B) Class I shifted motif sequence and example. 
Shown here is the C-terminal peptide of AG22 that was found to interact with ERBIN_PDZ.52 
 
Furthermore, recent array research reveals that some PDZ domains can recognize shifted 
motif peptide ligand.52 This motif denotes that capability of a PDZ domain to recognize the 
consensus sequence with one additional amino acid at the C-terminus; hence, this position is 
named P+1 (Table 1B).
52 There is no preference for the identity of the  amino acid at P+1, as long 
as a valine residue is at P0, implying that the residue at P+1 does not contribute to the specificity 
of PDZ domains.52 In particular, the PDZ domain of ERB2 interacting protein (ERBIN_PDZ) has 
been found to interact with the C-terminal peptide of the angiotensin II type 2 receptor (AG22) in 
vitro and the proteins are localized in vivo.52 The peptide sequence of AG22 resembles Class I 
ligand with an additional serine residue at the extreme C-terminus. Disassociation constant (KD) 
of ERBIN_PDZ binding interaction with canonical peptides ranges from 1 µM to 200 µM.52 The 
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additional residue at P+1 is predicted to decrease KD value by 10-15 fold, and the KD of AG22 
interacting with ERBIN_PDZ was 105.4 µM, measuring by surface plasmon resonance (SPR). 
Assisted model building with energy refinement (AMBER) was used to analyze for possible 
structural arrangements to help stabilize the complex structure in solution, using a crystal 
structure of ERBIN_PDZ. To accommodate for the additional serine residue, there was a twist in 
valine backbone that helped position valine deeper into its interaction area with ERBIN_PDZ. As 
a consequence, four new hydrogen bonds were established between ligands and nearby 
ERBIN_PDZ residues. The model supported that shifted motif had been adopted by 
ERBIN_PDZ, and possibly other PDZ domains.  
 
AF6_PDZ specificity  
The AF6_PDZ was originally classified as a Class II PDZ domain.48 It was later 
discovered that AF6_PDZ also has the ability to recognize both Class I ligands (Bcr) and Class 
III ligand (c-Src) as its binding partners (Table 2).31,34 Due to its wide range of ligand 
recognition, researchers used wide-array screening with 6223 C-terminal sequences derived from 
human proteins (6223-Humlib) to establish the specificity profile of AF6_PDZ.52  In this study, 
the 6223-Humlib library was generated by a modified SPOT synthesis, where the N-terminus of 
11-amino acid long (11-mer) peptides were attached to a cellulose membrane. The membrane 
was incubated with glutathione-S-transferase (GST)-tagged AF6_PDZ, followed by 
chemiluminescent substrate to identify peptides capable of binding AF6_PDZ. The 
chemiluminescence intensity was measured as Boehringer light unit (BLU). The intensities of 20 
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Table 2: List of known binders of the AF6_PDZ. X can be any residues and Φ is hydrophobic 
amino acid.8,30-34 
 
random spots were averaged and used as background intensity. Peptide binders were identified 
when their BLUs were two standard deviations away from the background intensity. Hence, a list 
of AF6_PDZ peptide binders was obtained. To determine KD of the binding interactions, twelve 
representative peptide sequences were selected to have their KD measure by SPR. These KD were 
used to calibrate the BLU values, and to obtain non-linear, least squares model to extrapolate KD 
from BLU values. Various amino acids were then substituted into the last four C-terminal 
peptide residues. The binding interactions of these mutated sequences with AF6_PDZ were 
measured as BLU, and these BLU values were fit into non-linear, least squares model to obtain 
KD. These KD and its corresponding peptide sequences were used to build the analysis of 
variance (ANOVA) model to predict KD based on sequence variance. The predicted KD were 
deviated by less than a factor of 2, with a few cases up to factor of 4, compared to measured KD 
by SPR. Furthermore, four of the representative peptides were studied by nuclear magnetic 
resonance (NMR) to provide estimated KD. The predicted KD from ANOVA were in agreement 
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with estimated KD by NMR (KD ranged from 33.1 µM to 137.4 µM). By utilizing ANOVA 
model, KD for peptide sequences bound AF6_PDZ from the 6223-Humlib library were predicted. 
The top 100 binding sequences were reported with estimated affinities in the mid-micromolar 
range, and the specificity profile for AF6_PDZ was summarized as (π/E)-(Φ/T/S)-x-ΨCOOH 
(where π is a small residue and Ψ is an aliphatic residue).52 Interestingly, within these top 100 
sequences, we found 23 sequences that did not abide by the AF6_PDZ specificity profile. As an 
example, SMLTKEL-Y-F-Y-H is a non-cognate peptide containing a bulky residue at position -
3, which normally has small amino acids, as well as a charged residue at position 0, which 
typically prefers aliphatic residues (deviated residues are highlighted in red).  
From the top 100 binding sequences, we also found 10 sequences that followed the 
shifted motif (Table 3).52 In fact, previous researchers performed a heteronuclear single quantum 
coherence nuclear magnetic resonance (HSQC NMR) titration with the C-terminal sequence of 
AG22 into 100 µM free AF6_PDZ.52 For a 1H-15N-HSQC NMR experiment, the protein is 
labeled with stable isotope of nitrogen, 15N. Magnetization starts at a proton and gets transferred 
to labelled nitrogen through bond, thus each amide proton shows one peak at specific hydrogen 
and nitrogen frequencies for its corresponding amino acid.54 The chemical shifts of each 
individual residue of a protein are quite sensitive to local chemical environment, thus changes in 
chemical shifts suggest changes in environment of amino acid. In the experiment of shifted motif 
ligand and AF6_PDZ, only small chemical shift changes at the final molar ratio 1:8 
(AF6_PDZ:peptide) were observed52, implying that the relative environments that each amino 
acid experienced in the presence of the ligand were not significantly different as in the free 
protein. However, since a low concentration of AF6_PDZ (100 µM) was used, weak binding 
interaction between the shifted motif peptide and AF6_PDZ could possibly not be detected. 
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Furthermore, surface representation of AF6_PDZ bound with Bcr reveals that there is a potential 
extended binding pocket at the far C-terminal of the peptide ligand, raising the possibility that 
this pocket can accommodate an additional residue at P+1 (Figure 6). Hence, the shifted motif 
binding mode needs to be investigated further for AF6_PDZ. 
 
 
Table 3: List of shifted motif sequences from the top 100 sequences. All the sequences have 
conserved residues at position 0 to -3.  
 
 
Figure 6: Surface representation of AF6_PDZ (gray) bound to Bcr (yellow) (PDB: 2AIN55). The 
extending binding pocket at the extreme C-terminus of peptide ligand is shown in box (red). 
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Binging interactions of AF6_PDZ with Class I and Class II ligand 
The solution structure of AF6_PDZ with a Class I ligand and a crystal structure of the 
complex between AF6_PDZ and a Class II ligand are available (Figure 7A and B).55,56 These 
structures highlight intermolecular interactions that stabilize the biological ligands at the binding 
pocket. The Gly-Met-Gly-Leu (Gly16-Met17-Gly18-Leu19) loop region that is located in the N-
terminus of βB has been referred to as the carboxylate binding loop, and it is a conserved 
sequence in many PDZ domains in term of hydrophobicity.33 These residues play an important 
role in the recognition of the C-terminus of the peptide ligand and maintaining a hydrophobic 
pocket to stabilize the side chain of a valine residue at P0 of the ligand.
33 The carboxyl group of 
the valine at P0 of a Class I ligand has been found to form hydrogen bonds with Gly18 and 
Leu19 of AF6_PDZ (Figure 7A).55 Additional hydrogen bonds are formed with Met17 of 
AF6_PDZ for a Class II ligand (Figure 7B).56 Moreover, the nearby residues, such as Ile21, 
Ala74, and Met77, also participate in establishing the hydrophobicity of the binding pocket 
(Figure 7C).55 Almost all known binders of AF6_PDZ have a valine at P0 demonstrating how 
these interactions play an important role in the binding interaction between AF6_PDZ and its 
physiological partners (Table 2).  
Comparing between Class I and Class II binding mode, available structures reveal 
differences between the two classes, such as the number of peptide residue that are critical for 
binding and the width of the binding groove. For Class I ligand, the amino acid at the P-4 has 
been found to be located at the edge of the binding groove and interact with Val22 of 
AF6_PDZ.55 This finding highlights that the last five residues of Class I ligand participate in 
binding interaction with AF6_PDZ (P0 to P-4). Conversely, for Class II ligand, the binding  
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Figure 7: Available structure of AF6_PDZ (green) bound with (A) Class I ligand (Bcr, PDB: 
2AIN, yellow)55 and (B) Class II ligand (nectin-3, PDB: 3AXA, cyan)56. Nitrogen atoms are 
shown in blue, and oxygen atoms in red. Hydrogen bonds are denoted by dashed lines. (C) 
Electrostatic surface of free AF6_PDZ (PDB: 1T2M)33. Blue regions are positively charged, 
while red regions are negatively charged. (D) Superposition of the AF6_PDZ with Bcr (yellow) 
and with nectin-3 (cyan). 
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interaction is primarily driven by the last three residues at the C-terminal end of the peptide (P0 
to P-2).
56 Alanine substitution for residue at P-3 of Class II ligand only slightly weaken the 
binding affinity, emphasizing its minor participation in the binding interaction with AF6_PDZ.56 
Furthermore, the αB helix of AF6_PDZ has been found to be displaced 2.5 Å away relative to 
the αB helix in the Class I binding mode (Figure 7D).56 Such displacement helps widening the 
binding groove to accommodate the bulky amino acid at the P-2 of Class II ligand. Altogether, 
the differences in binding interaction of AF6_PDZ with both class ligands illuminate the 
structural flexibility of AF6_PDZ that allows it to recognize and interact with these ligands. 
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Objectives of this project 
As elaborated above, PDZ domains are widely represented in human proteins, and play 
crucial roles in various transduction pathways. AF6 is large multidomain protein that functions 
as a scaffold to connect different components of signaling pathways. Specifically, its PDZ 
domain has been found to interact with many physiological partners. The main goal of my 
undergraduate research project was to identify important elements of peptide ligands that are 
crucial for binding AF6_PDZ. Knowledge of such elements can aid in designing therapeutic 
drugs targeting PDZ domains, generally, and the AF6_PDZ domain, specifically.  
To achieve the main goal, we first investigated the binding mode of AF6_PDZ with non-
cognate peptides. These peptides were shown to bind to AF6_PDZ in an array screening with the 
6223-Humlib library, however did not abide by the specificity profile of AF6_PDZ. Several non-
cognate peptides were chosen from the list of top 100 binding sequences that found to bind 
AF6_PDZ with predicted KD at a mid-micromolar range.
52 We hypothesized that the binding 
interface of AF6_PDZ would have to be plastic and allow AF6_PDZ to make accommodation 
for the deviated residues of the non-cognate peptides. Hence, the binding interactions between 
AF6_PDZ and these peptides were studied to elucidate the binding mode that the non-cognate 
peptides employed, and thereby highlight the important interactions that are crucial to promote 
binding. From the chosen peptides, we selected one non-cognate peptide as a representative. By 
using knowledge-based approach, specific elements were introduced to this peptide to restore 
binding with AF6_PDZ.  Based on the repeated appearance of valine at P0 in almost all 
AF6_PDZ known biological binders and its interaction with several residues of AF6_PDZ, the 
peptide was engineered with valine at P0 to evaluate the role of valine in the occurrence of 
binding. In addition, we were interested in studying the shifted motif further to confirm whether 
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the AF6_PDZ is able to recognized shifted motif peptide ligand, and if so, which structure of 
AF6_PDZ is flexible and allow the binding interaction to occur. Therefore, we engineered a 
valine residue at P-1 of the representative peptide to obtain shifted motif peptides, and studied the 
binding interaction. 
The binding interaction between AF6_PDZ and peptide ligands was studied 
predominantly by 1H-15N-HSQC NMR titration. The hydrogen and nitrogen frequencies can be 
used to compute combined chemical shift perturbations (CSPs).57 Significant CSP indicates 
specific residue experiencing a new chemical environment. CSP can be mapped on previously 
solved structure to highlight where binding interaction occurs57, and can be used to compare 
between complexes. One advantage of using this technique is relatively low cost to obtain 
isotopically labeled protein. Moreover, this technique fits extremely well for study protein 
binding interaction at the range of KD from 100 nM to 10 mM where our expected KD are 
within.54 Each residue of a protein is represented at a single peak on the spectrum with specific 
hydrogen and nitrogen frequencies; thus it is easy to detect degradation problem in the early 
phase of the project. The technique also allows us to learn more about kinetic and dynamic of the 
system, such KD and exchange rate between free and bound complexes.
54 
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III. Materials and Methods 
A. The PDZ domain of AF6, AF6_PDZ 
Expression and purification  
Residue 1003-1094 of the human AF6_PDZ sequence was inserted into the pET15b 
vector, which contains the ampicillin-resistance gene, by my direct supervisor, Ms. Marissa 
McKercher using standard cloning strategies. The original plasmid was AF6 in the pSGX3 
vector, as obtained from the DNASU online repository (https://dnasu.org/DNASU/). The 
AF6_PDZ_pET15b plasmid was transformed into chemically competent BL21 (DE3) E. coli 
cells for protein expression. The AF6_PDZ protein was expressed with a N-terminal 6xHis tag 
and a thrombin cleavage site, which could later be cleaved off by thrombin protease58 (Figure 8). 
 
 
Figure 8: Schematics of the PDZ domain AF6 expression construct. The AF6_PDZ was 
expressed with N-terminal 6xHis and thrombin cleavage site. Thrombin protease can be used to 
cleave off the tag to obtain the AF6_PDZ.58 
 
 
The E.coli were grown in Luria Broth (LB) with 1mM Ampicillin (LB_Amp). The cells 
were first grown in 50 mL LB_Amp at 37 °C overnight. This overnight culture was used to 
inoculate new 1 L volumes of LB_Amp with a dilution of 1:100. The new cultures were shaken 
at 37 °C until the optical density at 600 nm (OD600) reached between 0.6 and 1. The cell cultures 
were then cooled down on ice for 20 minutes prior to induction. Cells were induced with 0.5 mM 
of Isopropyl Beta-D-1 thiogalactopyranoside (IPTG), and the cell cultures were returned to 
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shaker at 20 °C overnight. Cell pellets were collected by centrifuging the cell culture at 4400 
relative centrifugal force (rcf), and frozen at -20 °C for later purification. 
For the isotopically labeled AF6_PDZ protein, the cells were grown in a minimal media 
(MM) with 1mM Ampicillin under identical conditions. To obtain MM, 1 L volumes of media 
that contained 25.0 mM Sodium Monohydrogen Phosphate Heptahydrate (NaHPO4 • 7H2O), 
22.04 mM Potassium Dihydrogen Phosphate (KH2PO4), 25.7 mM Sodium Chloride (NaCl), and 
11.2 mM Ammonium Phosphate ((15NH4)2SO4) was autoclaved. Then, a solution that was made 
up of 2 g glucose, 10 mL of MEM Vitamin Solution 100X (Life Technologies/Gibco), and 1 mL 
of metal mix stock (46 mM Boroic acid, 102 mM Calcium Chloride Dihydrate, 190 µM Cobalt 
Chloride Hexahydrate, 780 µM Copper Sulfate Pentahydrate, 1.02 M Magnesium Chloride 
Hexahydrate, 1 mM Manganese Chloride, 3 µM Sodium Molybdenum, and 1.7 mM Zinc 
Chloride) was prepared and filtered through cellulose acetate membrane with a pore size of 0.22 
µm. For 15N-13C-AF6_PDZ, 13C glucose was used. Prior to inoculation, the filtered solution was 
added into the autoclaved media together with 1 µM Iron (III) Chloride, and 100 µg/mL 
Ampicillin.  
The following purification protocol was obtained from Ms. Marissa McKercher, in which 
she had developed to purify the PLCγ1 protein, with minor modifications for AF6_PDZ protein.  
Cell pellets were thawed at room temperature. 50 mL of lysis buffer (100mM Potassium 
Phosphate (pH of 7.4), 200 mM NaCl, 1 mM Dithiothreitol (DTT), 25 mM Imidazole, and 0.2 
mM Phenylmethanesulfonyl Fluoride (PMSF)) was used to resuspend every 2 L of cell pellet.  
One protease inhibitor tablet (Roche) was added per each 50 mL of resuspension. The sample 
was lysed by sonication with 15 second pulses followed by 45 seconds off for a total pulse time 
of 2 minutes at an amplitude of 8. Insoluble materials were then removed by centrifuging at 
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42400 rcf. The supernatant, which contained the 6xHis AF6_PDZ, was applied to a gravity- flow 
flex-column from Kimble Chase (capacity: 20 mL, dimension: 7 x 500 mm) that contained 
nickel (Ni2+)-charged beads (Qiagen). 1 mL of Ni-charged beads was used per 1 L of cell pellet. 
The bound protein was first washed with 5 mL of a high salt buffer (100mM Potassium 
Phosphate (pH of 7.4), 1 M NaCl, 1 mM DTT, 25 mM Imidazole), then with 5 mL of an 
imidazole buffer (100mM Potassium Phosphate (pH of 7.4), 200 mM NaCl, 1 mM DTT, 60 mM 
Imidazole) to eliminate nonspecifically bound proteins. The 6xHis AF6_PDZ was eluted with 5 
mL fractions of elution buffer (100mM Potassium Phosphate (pH of 7.4), 200 mM NaCl, 1 mM 
DTT, 350 mM Imidazole) for a total of three 5 mL fractions. The samples of cell pellet, 
supernatant, flow-through solution, two washes, and three elution fractions were resolved by 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on a 17% gel to assess the 
quality of purification. 
Fractions that contained the AF6_PDZ with a minimal amount of impurities were 
concentrated down to a volume of approximately 2 mL, and cleaved with 10 units of thrombin 
protease per 1 mg of protein at 4 °C overnight. The AF6_PDZ protein was purified by G-75 size 
exclusion fast protein liquid chromatography (FPLC-SEC) in buffer (100 mM Potassium 
Phosphate (pH of 7.4), and 200 mM NaCl). Eluted protein was located by SDS-PAGE (17%), 
concentrated, and flash frozen in liquid nitrogen to store at -70 °C. Absorbance at the wavelength 
of 280 nm was measured, and the protein concentration was determined by using the extinction 
coefficient of 1490 M-1cm-1, as calculated using ProtParam. A typical purification of 2 L cell 
culture yielded 25-30 mg of protein. 
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Far-UV circular dichroism analysis  
Circular dichroism (CD) was used to confirm that the AF6_PDZ was properly folded. 
Cleaved AF6_PDZ was dialyzed into CD buffer (10 mM potassium phosphate (pH of 7.4), and 
10 mM sodium sulfate (Na2SO4)) by using Slide-A-Lyzer Dialysis Cassette from Thermo 
Scientific (capacity: 0.5-3 mL, 2000 molecular weight cut-off (MWCO)). The concentration of 
protein was 0.350 mg/mL. The spectra were collected with wavelengths ranging from 180 nm to 
260 nm in a 0.05 cm pathlength cuvette on a Chirascan Plus Circular Dichroism Spectrometer 
(Applied Photophysics). The initial CD spectrum was obtained at 20 °C.  For thermal melting 
analysis, spectra were collected at temperatures ranging from 5 °C to 85 °C in increments of 10 
°C. Upon completion, another spectrum was obtained at 20 °C to determine the ability of 
AF6_PDZ to refold after an unfolding event. 
Purification for Nuclear Magnetic Resonance (NMR) samples 
During the early phase of this project, cleaved 15N-AF6_PDZ was dialyzed into buffer 
(50 mM potassium phosphate (pH of 6.4), 1 mM ethylenediaminetetraacetic acid (EDTA), and 
50 mM NaCl) by using a Slide-A-Lyzer Dialysis Cassette (capacity: 0.5-3 mL, 2000 MWCO). 
The protein was concentrated, and prepared for NMR sample as outlined later. However, due to 
protein degradation, later experiments were performed on the 6xHis_AF6_PDZ. By leaving the 
His tag intact, the total purification time was reduced to eliminate protein degradation.  For these 
later experiments, after 6xHis_AF6_PDZ was eluted off the nickel column, the protein was 
concentrated to <2mL volume. Leaving the 6xHis tag intact, the 6xHis_AF6_PDZ was purified 
by G-75 FPLC-SEC in NMR buffer (50 mM potassium phosphate (pH of 5.8), and 1 mM 
EDTA). Eluted protein was concentrated, flash frozen in liquid nitrogen, and stored at -70 °C. 
Absorbance at the wavelength of 205 nm was measured, and the protein concentration was 
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determined by using the extinction coefficient at 205 nm as calculated by summing the extinction 
coefficients of the comprising amino acids (ɛ205 of AF6_PDZ = 378533 M-1cm-1).59 
 
B. Target peptides 
Plasmid preparation  
All of the peptides in this study had 11 amino acids. Considering that these short peptides 
could be a challenge for the cell to express and to be soluble, all peptides were produced as 
fusions with the highly soluble protein SUMO.60 Previous Wuttke lab member Ms. Timsi Rao 
had inserted the SUMO-protein sequence into the pET28b vector, which contained the 
Kanamycin-resistance gene and a 10xHis-tag amino-terminal to the SUMO. Site directed 
mutagenesis was used to insert DNA coding for desired peptides into the pET28b vector directly 
carboxy-terminal to the SUMO sequence. The primers for the peptides were designed by using 
online Primer Design Program from Agilent Technologies.61 Each primer had complementary 
sequence with the vector, as well as containing a coding sequence for target peptides. Codons 
were selected based on which codon is predominantly used by E. coli to code for each amino 
acid in genes that are highly expressed during exponential growth.62 The peptides were 
incorporated into the vector via polymerase chain reaction (PCR) using Pfu DNA polymerase. 
An initial cycle of 95 °C for 2 minutes was used to denature the parental DNA. Then, a cycle of 
95 °C for 30 seconds (denaturation), followed with 53 °C for 1 minute (annealing), and 68 °C for 
8 minutes (elongation) was repeated 18 times to allow peptide sequence insertion. The PCR was 
finished with a cycle of 68 °C for 10 minutes for final elongation. The PCR product was treated 
with 1 µL of DpnI restriction enzyme (20,000 Units/mL) to degrade the parental DNA63, and 
then transformed into XL1-Blue competent cells. The cells were grown on a Kanamycin-LB 
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plate. DNA was then extracted from these cells by using a Plasmid DNA mini kit (OMEGA) and 
sent out for sequencing by Genewiz to confirm successful insertion of the DNA coding for each 
peptide.  
Expression and purification of peptides as a SUMO-fusion protein 
The target peptides were expressed with N-terminal 10xHis-SUMO (Figure 9). Once the 
protein was purified, ULP1 protease could be used to cleave off N-terminal 10xHis-SUMO to 
obtain isolated peptide.64 The plasmid was transformed into and expressed in BL21 (DE3) E. coli  
 
 
Figure 9: Schematics of the targeted peptide expression construct. Targeted peptides were 
expressed with N-terminal 10xHis and SUMO. The 10xHis-SUMO tag could be cleaved off by 
ULP1 protease.64  
 
protein expression cells. In the presence of 1 mM kanamycin rather than ampicillin, the process 
of growing cells and obtaining cell pellets was identical to that previously described for the 
AF6_PDZ. 50 mL of lysis buffer (50 mM Tris (pH of 8.0), 150 mM NaCl, 10 mM Imidazole, 
5% Glycerol, and 1 mM β-Mercaptoethanol (BME)) was used to resuspend every 2 L of cell 
pellet. One protease inhibitor tablet was added per 50 mL of resuspension. The sample was lysed 
by sonication with 15 second pulses followed by 45 seconds off for a total pulse time of 2 
minutes at an amplitude of 8, and centrifuged at 424000 rcf. The collected lysate, which 
contained 10xHis-SUMO-peptide, was flowed over a nickel column. The bound protein was first 
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washed with 5 mL of high salt buffer (50 mM Tris (pH of 8.0), 1 M NaCl, 10 mM Imidazole, 5% 
Glycerol, and 1 mM BME), and then with 5 mL of an imidazole buffer (50 mM Tris (pH of 8.0), 
150 mM NaCl, 25 mM Imidazole, 5% Glycerol, and 1 mM BME). The protein was eluted with 5 
mL fractions of elution buffer (50 mM Tris (pH of 8.0), 150 mM NaCl, 350 mM Imidazole, 5% 
Glycerol, and 1 mM BME) for a total of three 5 mL fractions. The samples of cell pellet, 
supernatant, flow-through solution, two washes, and three eluted fractions were resolved by 
SDS-PAGE with 4-20% Precast Protein Gels from Bio-Rad. Eluted protein was concentrated, 
and further purified by G-75 FPL size exclusion chromatography in buffer (50 mM potassium 
phosphate (pH of 7.0), and 1 mM EDTA). The fractions that contained the protein were 
 
 
Table 4: Extinction coefficients of peptides at 205 nm. (A) ɛ205 of SUMO-fused peptides and 
isolated peptides. FXI1: forkhead box protein I1, EPA8: ephrin type-A receptor 8, KRAA: a-Raf 
proto-oncogene serine/threonine-protein kinase. (B) ɛ205 of SUMO-fused mutants. Mutation to 
peptide EPA8 is denoted in red. 
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collected, concentrated, flash frozen in liquid nitrogen, and stored in -70 °C. To be consistent 
with the AF6_PDZ, absorbance at the wavelength of 205 nm was measured, and the protein 
concentration was determined by using the extinction coefficient at 205 nm as calculated by 
summing the extinction coefficients of the comprising amino acids (Table 4).59 A typical 
purification of 2 L cell culture yielded 30 mg of protein. 
Cleavage and purification of isolated peptide  
After the 10xHis-SUMO-peptide proteins were eluted from the nickel column, the 
proteins were dialyzed into water by using Slide-A-Lyzer Dialysis Cassette (capacity: 3-12 mL, 
2000 MWCO). Upon recollection from the cassettes, the protein was concentrated to 600 µM. 
Ulp1 protease was then added at a ratio of 1:50 (Ulp1:protein) at 25 °C for 12-15 hours to cleave 
off the 10xHis-SUMO tag.64 TFA was added into the sample to the final concentration of 0.1% 
in order to promote peptide solubility. Peptides were purified by using reversed-phase high-
performance liquid chromatography (RP-HPLC). For all of the peptides, the transition from polar 
buffer A (95 % water, 5 % Acetonitrile (ACN), 0.1 % TFA) to nonpolar buffer B (100 % ACN, 
0.1 % TFA) was set at a flow rate of 5 mL/min. The injection volume was 500 µL. The method 
employed for individual peptides are listed in Table 5. Absorbance at wavelengths of 250 nm and 
210 nm was recorded. Fractions that had high absorbance were collected and analyzed further.  
The presence of each peptide in the solution was confirmed by matrix-assisted laser 
desorption/ionization time of flight (MALDI-TOF) using α-Cyano-4-hydroxycinnamic 
acid (CHCA) matrix (linear positive, laser intensity: 1300-2300, 50 shots per spectrum, mass 
range: 500-2000 Da). Fractions that contained the peptide were combined together, and 
neutralized by ammonium hydroxide (NH4OH) until the pH was above 4. The pH of the solution 
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was monitored by pH paper from Hydrion. The solution was lyophilized overnight to obtain 
isolated peptides in powder form. The isolated peptides were stored at -20 °C. 
 
 
Table 5: HPLC methods for purification of isolated peptides. Solution A is polar buffer (95 % 
water, 5 % ACN, 0.1 % TFA). Solution B is non-polar buffer (100 % ACN, 0.1 % TFA). 
 
C. Isothermal titration calorimetry (ITC) experiments 
ITC is a technique to measure heat production upon formation of binding complexes and 
was used to determine binding constants for protein/peptide interaction.65 The optimal KD range 
for ITC is 10 nM to 1 mM.65 Compared to NMR, one advantage of this technique is its ability to 
measure a KD of a tight binder under proper conditions. In some cases, ITC is less time-
consuming in total experiment time. In this study, in order to obtain a good resolution for the 
NMR spectrum, the experiment time between each titration point was six hours, which gave rise 
to a total experiment time of one week to obtain one complete set of titration data for a peptide. 
In contrast, an ITC experiment took approximately one hour to complete one set of titration data. 
Hence, ITC would be a desirable technique to determine KD for AF6_PDZ binding interaction.   
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 ITC experimental data were collected on a MicroCal™ iTC200 calorimeter. All 
experiments were performed in ITC buffer (100 mM Potassium Phosphate (pH of 7.4), and 200 
mM NaCl) at 25 °C.  For each experiment, there was 23 injections with an initial delay of 120 
seconds. The reference power was set at 11 µcal/sec, the stirring speed was 1000 rpm. The 
spacing between each injection was 180 seconds. The injection parameters are detailed in Table 
6. The volume of syringe and cell were 40 µL and 300 µL, respectively.  Due to insufficient heat 
production from early injections, initial injections of 0.2 µL and 0.5 µL were omitted from data 
analysis. The final injection of 0.4 µL was also omitted because it was set up to inject any 
remaining solution from the syringe.  
 
 
Table 6: ITC injection parameters. 
 
In order to obtain a good data set, c-window (c-value) of approximately 10 was used. c-
value is used to identify an optimal range of experimental conditions that provide a fitted data 
with confidence. Previous research had shown that AF6_PDZ binds a Class I ligand with an 
approximate KD of 100 µM.55,66 With this estimated KD, the protein concentration needed was 
calculated to be 1 mM, and the ideal peptide concentration used was around 10-fold higher.  
Isolated cognate peptide (GVLYPREGTEVCOOH) was resuspended into 60 µL buffer to obtain 
the desired concentration. Absorbance at the wavelength of 205 nm was measured, and the 
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extinction coefficient (Table 4A) was used to determine the concentration of cognate peptide. 
11.06 mM peptide was titrated into 1.10 mM AF6_PDZ to collect raw data. The titration data 
was processed by Origin Software, and fitted with a model for one set of binding site. The 
thermodynamic parameters were then computed by the software. Two control experiments were 
performed to detect any heats of dilution or mixing: titration of 11.06 mM peptide into the 
buffer, and titration of the buffer into 1.10 mM AF6_PDZ. The titration of the buffer into the 
protein did not provide significant heat signal, but there was significant heat production in the 
titration of the peptide into the buffer. Furthermore, this heat production followed a distinctive 
pattern. Due to this reason, this data was used as a reference data and subtracted from peptide-to-
protein titration data, instead of averaging the heat signal production. The data were subtracted 
from the peptide-into-protein titration data before the titration data was processed as outlined 
above. In consideration of the high concentration of protein and peptide being used, the 
instrument went through deep cleaning before and after each run with 20% ContradTM (GE 
Healthcare).  
 
D. Nuclear magnetic resonance (NMR) instrumentation and sample preparation 
All NMR experiments were recorded on an Oxford 600 MHz spectrometer equipped with 
an Agilent console and HCN PFG cold probe at 25 °C. Spectra were processed with NMRPipe 
and visualized with CcpNmr Analysis.67,68 In order to complete backbone assignments, four sets 
of triple-resonance experiments were performed: HNCA, HN(CO)CA, HNCACB, and 
CBCA(CO)NH. The 15N-13C-6xHis-AF6_PDZ was in NMR buffer (50 mM potassium phosphate 
(pH of 5.8), 1 mM EDTA, and 10% D2O) at a concentration of 1.0 mM. 
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 The 1H-15N-HSQC NMR titration experiments were performed with the parameters 
loaded with the Biopack gNhsqc.c pulse sequence available with the Vnmrj software except as 
changed below. The NMR parameters were set up as follows: sweep width (sw) = 11990.4 Hz, 
sweep width of indirect dimension (sw1) = 2350 Hz, steady state scans (ss) = 64, number of 
transients (nt) = 56, number of increments (ni) = 120, number of points (np) = 2048, gain = 32, 
relaxation delay (d1) = 1.5, pulse width (pw) = 9.0 ± 0.5, transmitter power (tpwr) = 53, pulse 
width for nitrogen dimension (pwN) = 36.0, power level for the nitrogen pulse (pwNlvl) = 60, 
carrier offset for nitrogen dimension (dof2) = 1337 Hz, 15N decoupling power (dpwr2) = 37, and 
a wurst40 decoupling pattern for 15N. Water suppression and proton pulses were calibrated in 
each experiment.  
The AF6_PDZ protein concentration was 0.5 mM for 1H-15N-HSQC NMR titration 
experiments, unless otherwise indicated. Isolated peptides were resuspended into buffer (50 mM 
Potassium Phosphate (pH of 5.8) and 1 mM EDTA). The peptides were titrated into AF6_PDZ in 
the same buffer with 10% D2O to achieve a final excess molar ratio (protein:peptide) of 1.50 in 
the following increments: 0.25, 0.5, 0.75, 1.0, 1.25, 1.50. At the beginning of an experiment, an 
initial NMR spectrum was obtained for free protein to assess the quality of protein. For each 
titration point, protein sample was recollected from the 5 mm Shigemi thin-wall sample tube. 
0.25 molar ratio of peptide was added into the sample and thoroughly mixed prior to data 
acquisition.  
Due to the insolubility of the 10xHis-SUMO-peptides at pH of 5.8, later titration 
experiments were performed at a pH of 7.0. The 10xHis-SUMO-peptides were concentrated in 
buffer (50 mM potassium phosphate (pH of 7.0) and 1 mM EDTA) and titrated into AF6_PDZ in 
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the same buffer with 10% D2O to achieve a final excess molar ratio of 2 in the following 
increments: 0.5, 1.0, and 2.0.  
All NMR data were collected by my graduate supervisor, Ms. Marissa McKercher. The 
NMR samples were prepared by me. My supervisor provided technical support in setting the 
parameters and run the NMR experiments on the samples. Between titration experiments, I 
recollected the protein samples and added an appropriate amount of a peptide ligand. Upon the 
completed collection of the NMR data, the data were then processed, and analyzed by me.  
 
E. Chemical shift mapping and disassociation constant KD estimation 
From the NMR data, combined chemical shift perturbations (CSPs) for each amino acid 
of AF6_PDZ were calculated using the equation69: 
CSP (ppm) =  √(ΔH)2 + (0.17 × ΔN)2   
where ΔH is the chemical shift change (in ppm) of the amide proton between free and bound 
states of AF6_PDZ, and ΔN is chemical shift change in nitrogen dimension. 
A previously solved structure of AF6_PDZ bound to Bcr (Protein Data Bank: 2AIN55) 
was visualized by PyMOL.70 This structure was used as a model for this project. CSPs were 
calculated for all residues for AF6_PDZ using the final NMR spectrum for each titration, at 
which point AF6_PDZ should be fully saturated with ligand. Depending on the CSP magnitude 
of each amino acid, the residue was categorized into a group: yellow (0.07 ppm < CSP < 0.1 
ppm), orange (0.1 ppm < CSP < 0.2 ppm), and red (CSP > 0.2 ppm). White color was used for 
residues that either were not observed in the free AF6_PDZ spectrum or disappeared upon 
36 
 
addition of peptide. Once all residues are assigned into their group, the residues were colored and 
mapped on the previously solved structure.  
CSPs were then used to estimate the disassociation constant (KD). At each titration point 
for a peptide, CSPs were calculated for several residues that experienced a significant chemical 
shift change. The CSPs were plotted as a function of the concentration of ligand present in 
solution to generate a titration curve. Non-linear regression analysis was performed using the 
Solver add-in available in Microsoft Excel to extrapolate the KD. The data was fit with the 
equation71: 
CSP = CSPmax ×
(KD + [P]T + [L]T − √(KD + [P]T + [L]T)2 − (4 × [P]T ×  [L]T)
2[P]T
 
where CSPmax is calculated with the final titration data (when AF6_PDZ is fully peptide-bound), 
[P]T is total protein concentration, and [L]T is total ligand concentration. 
To evaluate how well the data was fit, sum of squared residuals (SSR) was calculated for 
each non-linear regression plot. SSR is the sum of differences between the observed CSP and the 
calculated CSP. The low SSR value corresponds to a high probability that the data is correctly 
fit.72 In this thesis, SSR value that was larger than 1.0 x 10-4 implied that the data was not fit 
properly, and thereby the estimated KD for the residues with high SSR values were omitted in 
calculation of the mean and standard deviation of KD. 
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IV. Results 
Assignments of AF6_PDZ residues 
Protein expression and purification. The 6xHis-AF6_PDZ protein expressed well in BL21 (DE3) 
E.coli cells (Figure 10A). During the initial phase of this project, the 6xHis tag was cleaved by 
thrombin protease58, and the AF6_PDZ was purified by size exclusion chromatography using an 
FPLC system. Cleaved AF6_PDZ was found in two different peaks in the size exclusion 
chromatogram (Figure 10B). Based on its molecular weight (MW), the AF6_PDZ was expected 
to elute in the 85 mL fraction. This elution volume corresponded to the second peak. Conversely, 
the MW of the protein in the first peak was estimated to be 28 kDa using its elution volume. This 
MW was 3-fold higher than the MW of AF6_PDZ (MW = 9.83 kDa), suggesting that AF6_PDZ 
was forming a higher order complex in solution. Fractions from the first peak were analyzed by 
non-reducing SDS-PAGE. In all samples, there was only one protein band observed at the 
molecular weight of AF6_PDZ monomer (Figure 10C). Even though the protein band was 
slightly shifted in non-reducing SDS sample, this band does not correspond to a 28 kDa species 
and likely just reflects the differential mobility of the oxidized and reduced species in the gel. 
This result implies that the higher molecular weight species (multimer) is not formed by disulfide 
bonds. Furthermore, FPLC-SEC fractions from the first peak were pooled, concentrated, and 
reinjected into the G75 column. The reappearance of the monomer peak in the chromatogram 
supports the conclusion that there is an equilibrium between the monomer and the multimer of 
AF6_PDZ in the solution. The AF6_PDZ monomer/dimer equilibrium has been observed by 
other researchers, and dimerization does not impact the protein conformation.55 Therefore, all 
fractions from both peaks were pooled, and used all proceeding experiments. 
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Figure 10: Purification of AF6_PDZ. (A) SDS-PAGE gel of samples collected from nickel 
column purification (MW of 6xHis-AF6_PDZ is 11.72 kDa). (B) FPLC-SEC chromatogram of 
AF6_PDZ.  The multimer and monomer of the protein were found in peaks around 65 mL and 80 
mL elution respectively. (C) SDS-PAGE gel of sample collected from the peak of the multimer. 
Shown here is the same sample prepared with and without DTT (MW of AF6_PDZ is 9.83 kDa). 
 
Confirmation the proper folding of AF6_PDZ. Circular dichroism (CD) was used to assess the 
secondary structure of the AF6_PDZ and confirmed that the protein is properly folded. By using 
a previously available structure of the protein33, the expected characteristics for AF6_PDZ are 
14.6 % α-helix, 37.5 % β-sheet, 16.7 % β-turn, and 31.2 % random coil content. The initial CD 
data at 20 °C reveals that our protein has 17.4 % α-helix, 34.7 % β-sheet, 16.5 % β-turn, and 31.3 
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% random coil contents over wavelength range of 190 nm to 260 nm. These percentages are 
close to the expected values for AF6_PDZ, confirming that the protein is folded into a correct 
conformation. The CD spectra are shown in Figure 11A. We also performed a thermal melting 
analysis to identify the temperature at which protein denaturation would start to occur. At 
temperatures above 35 °C, the spectra begin to resemble the random coil spectrum (Figure 11B).  
 
 
Figure 11: CD spectra of AF6_PDZ. (A) Initial CD spectrum at 20 °C. (B) CD spectra of 
AF6_PDZ at various temperatures. (C) Melting temperature analysis at a wavelength of 208 nm. 
(D) Final CD spectrum at 20 °C. 
 
Furthermore, a plot of the absorbance at wavelength of 208 nm as a function of temperature 
reveals that the protein starts to denature at 45 °C (Figure 11C). Upon the completion of thermal 
melting analysis, a final spectrum at 20 °C was collected to inspect the ability of AF6_PDZ to 
refold to determine if the process is reversible. The spectrum has similar characteristics to the 
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initial spectrum (Figure 11D), confirming that denatured AF6_PDZ can refold into its 
conformation at 20 °C. 
 
1H-15N-HSQC NMR of free protein. The initial 1H-15N-HSQC NMR of cleaved AF6_PDZ was 
obtained at the pH of 6.4. The spectrum was not well-resolved. There were more peaks observed 
than we expected, and these peaks were localized and overlaid in the area that residues of 
unstructured region were expected. This result indicates that degradation was present in the 
sample. Because of the long time elapsed from the nickel chromatography to the NMR sample 
preparation (the total time was 3 days), we hypothesized that the protein degradation was time-
sensitive. To reduce the total time of purification, the 6xHis tag remained intact to eliminate the 
need for an overnight protease cleavage. The protein was purified directly into the NMR buffer 
to remove the additional overnight dialysis. The HSQC NMR spectrum is well-resolved with 
excellent peak line widths and intensity. Furthermore, there are fewer peaks observed at the 
region associated with an unstructured/degraded protein (Figure 12), indicating that we reduced 
the protein degradation in the sample. The AF6_PDZ domain has 92 amino acids, in which one 
residue is a proline (Pro4) and not observed in the spectrum. There are 21 residues from the N-
terminal His tag and thrombin cleavage site, but these residues are likely flexible so may not be 
observable. Altogether, the expected number of peaks is 112. The observed number of peaks is 
99. The lower number of observed peak than expected suggests that the His tag was not fully 
observable, as we will discuss in the next section. 
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Figure 12: 1H-15N-HSQC NMR spectrum of 500 µM AF6_PDZ with complete assignments at a 
pH of 5.8 (50 mM Potassium Phosphate, 1 mM EDTA) at 25 °C The spectrum was collected 
with the parameters: sw1 = 2300 Hz, ni = 210, and nt = 88. 
 
Protein backbone assignments. Full resonance assignments were obtained using standard triple 
resonance NMR methods. The assignment of 6xHis-AF6_PDZ amino acids was done at pH 5.8. 
Four sets of triple-resonance experiments were performed (HNCA, HN(CO)CA, HNCACB, and 
CBCA(CO)NH). Assignments were made by connecting adjacent residues based on the unique 
Cα and Cβ chemical shift of each amino acids (Figure 13). All residues of AF6_PDZ are 
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assigned, except Met17 and Pro4 (see Appendix 1). The Met17 peak is not observed at the pH of 
5.8, possibly due to its location at the flexible loop between βA and βB. The Lys2, Glu3, and 
Ala27 peaks are overlaid. There are 10 peaks observed from the His tag. The assignments are in 
agreement with previously published data.32 An HSQC NMR spectrum of free AF6_PDZ with 
complete assignments is shown in Figure 12.  
 
 
Figure 13: An example of the assignment of 78Thr-79Arg-80Thr-81Ser. HNCACB (Cα in cyan, 
Cβ in red). CBCA(CO)NH (Cα and Cβ of proceeding residue in purple). 
 
Due to the solubility limitations of SUMO-tagged peptides at a pH of 5.8, later 
experiments were performed at a pH of 7.0. The quality of the spectrum remains the same, 
suggesting changes in pH does not affect the protein conformation. Since the spectra are 
essentially identical, all of the assignments are able to be reliably transferred (Figure 14). There 
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are several peaks, however, that disappeared upon the change in pH, such as Gln14, Asn15, 
Gly16, Gly18, Gly28, Val39, Ser81, and Ser82. All of these peaks are located at various loop 
regions of the protein, suggesting changes in the pH of the solution may affect the chemical 
exchange regime of peaks located in loop regions. Asp46 peak has low intensity in both spectra. 
 
 
Figure 14: 1H-15N-HSQC NMR spectra of 500 µM AF6_PDZ at a pH of 5.8 (red) and at a pH of 
7.0 (purple). The spectra were collected with the parameter: sw1 = 2350, ni = 120, and nt = 56. 
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Cognate peptide binding interactions with AF6_PDZ 
Protein expression and purification. Cognate peptide (FXI1: GVLYPREGTEVCOOH), a Class I 
ligand (x-S/T-x-Φ-COOH), was chosen from the list of the top 100 binding sequences because 
its sequence follows the specificity profile of AF6_PDZ.52 Considering that the peptide has only 
11 amino acids, the peptide may be insoluble and difficult for the cells to express. Therefore, the 
peptide was expressed with a highly soluble SUMO protein; then Ulp1 protease was used to 
cleavage off the SUMO tag to obtain the isolated peptide.60,64 The SUMO-tagged peptide was 
well-expressed (Figure 15A). Once the protein was eluted from the nickel column, fractions that 
contained the protein were cleaved by Ulp1 protease, and purified by RP-HPLC (Figure 15B). 
MALDI-TOF confirmed the presence and purity of cognate peptide in the 12 minutes fraction 
(Figure 15C), while SUMO was eluted at 21 minutes fraction.  
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Figure 15: Purification of isolated cognate peptide. (A) SDS gel of samples from nickel 
purification (MW of SUMO-fused peptide is 15.4 kDa). (B) RP-HPLC chromatogram of a 
typical injection. (C) MALDI-TOF of fraction that eluted at 12 minutes (MW of cognate peptide 
is 1306.4 Da). 
 
1H-15N-HSQC NMR titration. Cognate peptide was titrated into AF6_PDZ until a final molar 
ratio of 1:1.5 of protein:peptide was reached (Figure 16A). The majority of peaks are in the fast 
exchange regime (such as Thr10), meaning the chemical shift of these peaks are the weighted 
average of the chemical shifts of the free protein and of the protein peptide complex.73 
Furthermore, several of these peaks have some curvature in the way how they walk, for instance 
Lys37 and Glu71, suggesting that the residues experience a mixed chemical exchange regime 
between an intermediate and fast exchange or possibly encounter different chemical exchange 
regimes in one dimension versus the other. Several peaks are in the intermediate exchange  
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(A) 
 
(B) 
 
Figure 16: 1H-15N-HSQC NMR titration of cognate peptide into AF6_PDZ at a pH of 5.8 (50 
mM Potassium Phosphate, 1 mM EDTA) at 25 °C. 0.25 molar peptide was added in increments 
until the final molar ratio of AF6_PDZ:peptide reached 1:1.50. Thr10 and Ser81 are examples of 
residues in the fast and intermediate exchange regimes, respectively. 
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regime (such as Ser81) (Figure 16B), in which we observe the peak intensities decrease when 
increasing the peptide concentration, and the peak eventually disappear and only reappear at the 
high concentration of the ligand.73 There are two slow exchange peaks (Gly18 and Gly54). These 
peaks disappear during the course of titration and reappear with weak intensities at different 
chemical shifts at the final titration point (1:1.5 molar excess peptide). The weak intensities of 
these peaks suggests that the AF6_PDZ is not fully saturated with peptide. Various fast and 
intermediate exchange peaks are also experiencing minor movement at the last titration point, 
further supporting that the protein was not saturated at the 1:1.5 excess molar ratio of ligand. 
Later experiments were consequently performed up to 1:2 excess molar ratio of ligand to ensure 
that AF6_PDZ was fully saturated by the end of the peptide titration.  
Not all non-cognate/mutant peptides were able to be purified as isolated peptides due to 
RP-HPLC and buffer incompatibilities, as will be discussed later. Therefore, in the later phase of 
this project, peptides were left intact with the SUMO tag. In the presence of the SUMO tag, the 
SUMO-tagged peptides were insoluble in the NMR buffer at pH of 5.8 likely due to the fact that 
the isoelectric points (pI) of these proteins are around 6. Therefore, we shifted our system to 
study the binding interaction at the pH of 7.0 to promote protein solubility. As a control for these 
later SUMO-tagged peptides studies, isolated SUMO protein was purified, and titrated into free 
AF6_PDZ at the final molar ratio of 1:1 (Figure 17). There are no chemical shift changes 
observed relative to the free protein, suggesting that the SUMO protein does not interact with 
AF6_PDZ.  
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Figure 17: 1H-15N-HSQC NMR titration spectrum of isolated SUMO protein into 500 µM 
AF6_PDZ at a pH of 7.0 (50 mM Potassium Phosphate, 1 mM EDTA) at 25 °C. 
 
Furthermore, the 10xHis-SUMO-tagged cognate peptide was titrated into free AF6_PDZ 
at the pH of 7.0 (Figure 18). This experiment was done to ensure that the presence of SUMO 
protein does not affect the ability of the ligand to be recognized by the AF6_PDZ and vice versa. 
In the previous titration with an isolated peptide, we learned that the AF6_PDZ was not saturated 
at an excess of a 0.5 molar ratio of ligand. Therefore, SUMO-tagged cognate peptide was titrated  
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Figure 18: 1H-15N-HSQC NMR titration spectrum of SUMO-tagged cognate peptide into 500 µM 
AF6_PDZ in NMR buffer at a pH of 7.0 (50 mM Potassium Phosphate, 1 mM EDTA) at 25 °C. 
 
into AF6_PDZ with an excess molar ratio of 2:1 peptide to ensure the protein was saturated. 
Overall, the bound spectra are nearly identical, meaning that peaks that experienced significant 
chemical shift changes remain the same regardless of the change in pH or the presence of SUMO 
protein (Figure 16 and 18). In a pH of 7.0 experiment, there is a reappearance of Gly18 and 
Gly54 at the final titration point. Moreover, Gly28 and Gly16 reappear, while Leu19 and Ile21 
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disappear upon the addition of peptide ligand. These observations suggest that these amide 
protons are in the intermediate-exchange timescale. Asp46 disappear in the presence of the 
ligand. However, Asp46 already has a low intensity in the free protein spectrum; thus, it is 
possible that its intensity is decreased upon the addition of peptide so it cannot not be detected by 
our NMR conditions. The protein chemical shift perturbation (CSP) data for the titrations of 
cognate peptide with and without the SUMO tag are plotted side by side for comparison (Figure 
19). Since changes in pH does not alter the chemical shifts, for residues that reappear during the 
course of the titration, the chemical shifts in the free protein spectrum at a pH of 5.8 were used to 
calculate the CSP. In the presence of the SUMO tag, the CSP trend remain the same. The CSP 
magnitudes of all residues increase likely because the protein is fully saturated in the titration 
with the SUMO-tagged peptide. These results strongly support that, regardless of the pH of the 
solution, the SUMO-tagged peptide interacts with AF6_PDZ in the same manner as does the 
isolated peptide. Residues that are significantly perturbed are located at βB, βC, αA, αB, and 
various loop regions of AF6_PDZ. αB and βB form the binding groove for the peptide ligand 
insertion so the large chemical shifts changes of residues located on these structure are expected. 
Chemical shifts of residues in αA, βC, and various loops regions are also perturbed, possibly due 
to the minor structural rearrangement to accommodate the changes in the protein backbone in the 
presence of the ligand. These protein regions with significant chemical shift changes are also 
observed by others before.32,66  
 
 
51 
 
 
Figure 19: Comparison plot of the protein CSP of cognate peptide titration as an isolated peptide 
at a pH 5.8 (blue) and as a fusion with the SUMO protein at a pH of 7.0 (red). Chemical shift 
changes that above 0.1 ppm are significant.   
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Disassociation constant KD. The KD of the binding interaction between cognate peptide and 
AF6_PDZ was measured by ITC. For ITC experiment, two control experiments were performed 
to detect any heats of dilution or mixing. The protein-into-buffer control experiment did not 
show significant heat (Figure 20A), suggesting that the heat of the protein dilution is negligible. 
However, when the peptide was titrated into the ITC buffer, there is significant heat production 
(Figure 20B). This heat production is likely a result of buffer mismatch, possibly due to TFA that 
carried over from the RP-HPLC purification, thereby altering the pH of the peptide solution. 
Upon subtracting the heat from peptide dilution, the peptide-to-protein titration data was fit 
(Figure 20C). The KD is 1.2 mM with a number of binding site of 0.96, supporting the expected 
single binding site model of PDZ domain/peptide binding. The change in enthalpy is -3.3 x 104 
cal/mol, and the change in entropy was -96 cal/mol/deg. The experiment was repeated two more 
times; however, the result was not reproducible. These later experiments had a number of 
binding sites that were significantly away from 1 (0.55 and 0.72), suggesting these titration data 
are not properly fit. This improper data fit can possibly be due to the discrepancy in subtracting 
the reference data. Although the same peptide solution was used for peptide dilution control and 
three titration experiments, the ITC experiments were performed over several days so the peptide 
might behave differently over time producing other patterns of heat production from the peptide 
dilution control data.  
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Figure 20: ITC experiments to determine KD of cognate peptide binding interaction. (A) Protein 
dilution control, in which buffer was titrated into AF6_PDZ. (B) Peptide dilution control, in 
which peptide was titrated into buffer. (C) Raw data of peptide-into-protein titration (left) and 
subtracted data (right). 11.06 mM peptide was titrated into 1.10 mM AF6_PDZ in ITC buffer. 
 
Considering that there was high heat production due to buffer mismatch, ITC is not an 
ideal technique to determine the binding affinity of this weak binding interaction system. The 
optimal KD range for ITC is 10 nM to 1 mM
65, where the binding affinity of our system is close 
to the upper limit of this KD range, in which it is a challenge to obtain an accurate KD for the 
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cognate peptide binding. Another alternative approach to determine KD is to extrapolate the KD 
value from the HSQC NMR titration data. 
The protein CSP data of isolated peptide titration were used to compute KD. Peaks that 
experienced significant changes were selected for this analysis (Table 7), and non-linear 
regression plots are shown in Figure 21. Residues provided precise KD values with low sum of 
squared residuals (SSR), implying that the calculated CSPs were close to the observed CSPs with 
minimal error. The estimated KD from these residues is approximately 154 µM with standard 
deviation of 78.6 µM. Lys37 was omitted from the calculation of the average KD because it is an 
outlier, in which it suggests a KD value that is significant away from the values of other residues.    
 
 
Table 7: Estimated KD of cognate peptide binding interaction from various residues that had 
significant chemical shift changes. Outlier is marked with asterisk. 
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Figure 21: Non-linear regression analysis to estimate KD of cognate peptide binding interaction. 
Shown here is the CSP data of Gln70. The observed CSP values are in blue, while the calculated 
CSP values are in orange. 
 
Altogether, comparing the NMR and ITC titration experiments, the average KD as 
determined by NMR is likely to more representative of the actual binding interaction between the 
cognate peptide and AF6_PDZ. In fact, our average KD of 154 µM is in agreement with the 
previously reported KD value of Class I ligand Bcr (110.9 µM
56 and 120 µM66).  
 
Non-cognate peptides  
Expression and purification. Several non-cognate peptides were selected from the list of top 100 
binding sequences52, based on their residues deviated from the specificity profile of AF6_PDZ 
(Table 8). Similar to the cognate peptide, these peptides were expressed with the SUMO protein 
to promote solubility. The peptide (ICE3: SMLTKELYFYHCOOH) was not well-expressed in 
BL21 (DE3) expression cells. Furthermore, peptide (ELAF: GSCGMACFVPQCOOH) was 
precipitated during the purification process, even with the soluble SUMO tag. These two 
peptides were not studied further due to these expression and purification challenges. The other 
two peptides (EPA8: MENGSLDTFLRCOOH, and KRAA: ACLLSAARLVPCOOH) were well- 
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Table 8: List of cognate and non-cognate peptides in this study. Deviated residues are in red. 
 
 
Figure 22: RP-HPLC chromatograms and MALDI-TOF spectra of EPA8 (A) and KRAA (B). 
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expressed, cleaved by Ulp1 protease, and purified by RP-HPLC. Their HPLC chromatograms 
showed sharp peaks for the peptide (Figure 22), indicating the sample was pure. The presence of 
peptide EPA8 in the solution was confirmed by MALDI-TOF (Figure 22A). We also observed 
an additional species 16 g/mol larger than EPA8. This MW could correspond to the addition of 
an oxygen atom, suggesting that the peptide may have been oxidized. The oxidation possibly 
occurred on the methionine residue, in which methionine sulfoxide was formed. However, since 
this residue was located at the extreme N-terminus of the peptide (a position typically not 
involved in PDZ domain binding) and the oxidized peptide was not the dominant species present 
in the sample, the oxidation would not be predicted to interfere with the binding interaction of 
the peptide to AF6_PDZ. 
The presence of peptide KRAA in solution was also confirmed (Figure 22B), though 
there was an additional higher MW species dominantly presented in the sample. The difference 
in MW is 77 g/mol, suggesting that there is possibly a counter ion or other modification to the 
peptide. Due to limited solubility in the NMR buffer, we also engineered two versions of KRAA 
with additional charged residues at the N-terminus of the peptide; either two lysine residues or 
two glutamic acid residues. These peptide variants were expressed and purified in the same 
manner as the unmodified KRAA peptide. MALDI-TOF spectra of these peptides show similar 
patterns, in which there are also the presence of the higher MW species. This higher MW species 
is the KRAA peptide that possibly has the thiol side chain of cysteine forming a disulfide bond 
with BME. Since the cysteine residue is located in the N-terminal end, similar to the EPA8, the 
modification should not interfere the binding. 
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1H-15N-HSQC NMR titration. The purified non-cognate peptides were redissolved in the NMR 
buffer at a pH of 5.8, and titrated into free AF6_PDZ to a final molar ratio of 1:1. Unlike the 
cognate peptide, the KRAA peptide had limited solubility in the NMR buffer as a result of its 
hydrophobicity. As a consequence, the concentration of AF6_PDZ was lowered to 440 µM to 
accommodate the solubility limit of the KRAA peptide. For both non-cognate peptides, there 
were not many significant chemical shift changes observed (Figure 23). In both system, there 
were only five peaks that experienced fast exchange chemical shift changes: Gly18, Ser20, 
Gly54, Met77, and Thr78. These residues had significant chemical shift changes in the binding 
interaction with the cognate peptide (Figure 16). This result suggests that the non-cognate 
peptides only weakly interact with AF6_PDZ, and are not likely physiologically relevant binding 
partners. 
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Figure 23: 1H-15N-HSQC NMR titration of non-cognate peptide (EPA8) into 500 µM AF6_PDZ 
at a pH of 5.8 (50 mM Potassium Phosphate, 1 mM EDTA) at 25 °C. 
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Designed peptides  
Mutant peptides design. The non-cognate peptides chosen for study based on the findings of 
Boisguerin were unable to bind AF6_PDZ. To elucidate important elements of the ligand for 
protein binding, we used a knowledge-based rationale design approach to introduce mutations 
into one of the non-cognate peptides to identify mutations capable of restoring the binding 
interaction.  
   Due to the potential unknown modification of the peptide KRAA, the peptide EPA8 
(MENGSLDTFLRCOOH) was selected for mutant design. A valine residue appears at the C-
terminal end of almost all known biological ligands of AF6_PDZ (Table 2) and available 
structure shows its crucial interaction with AF6_PDZ.55,56 In order to mimic this established 
specificity profile, the first mutant of this study was obtained by replacing arginine for valine at 
the P0 of the peptide ligand (R0V: MENGSLDTFLVCOOH) (Table 9). This mutation makes the 
peptide a Class II ligand since it has the motif of x-Φ-x-Φ-COOH.  
 
 
Table 9: List of cognate and mutant peptides in this study. Mutated residues are in red. 
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Furthermore, we were interested in the ability of AF6_PDZ to recognize shifted motif 
peptide. The shifted motif peptide is a peptide that follows the specificity profile and has an 
additional residue at the extreme C-terminus of the peptide.52 For example, the PDZ domain of 
ERB2 interacting protein (ERBIN_PDZ) has been found to interact with the C-terminal peptide 
of the angiotensin II type 2 receptor (AG22) with an affinity of 102 µM, and the stimulated 
model of ERBIN_PDZ bound with AG22 shows that a twist in a valine backbone of the peptide 
ligand allows valine to position deeper into the binding pocket for the binding interaction to 
occur.52 In the same study, AG22 has been shown to not bind to AF6_PDZ.52 However, the low 
concentration of protein could cause the binding interaction not detected by a NMR experiment. 
Moreover, available structure shows that there is a potential extended binding pocket located 
upstream of the C-terminus of the peptide ligand (Figure 6), which is formed by two loop 
regions. We hypothesize that the loops might be flexible and allow AF6_PDZ to recognize a 
peptide ligand with an additional C-terminal amino acid. Therefore, we mutated a leucine residue 
to a valine residue at the original P-1 of EPA8 to obtain a shifted motif ligand (L-1V: 
MENGSLDTFVRCOOH). By doing so, the L-1V peptide would follow a Class I shifted motif 
ligand with an arginine residue at its P+1. In the top 100 binding sequences identified by 
Boisguerin, there are 10 sequences that followed the shifted motif.52 These sequences 
predominantly have a serine/threonine residue at the P+1 (Table 3). In light of this, we designed 
an additional double mutant peptide by replacing the arginine to a serine at the P+1 (DM: 
MENGSLDTFVSCOOH), in consideration that serine may be a preferable residue. 
 
Expression and purification. Aa above, all of the mutant peptides were well-expressed as a 
fusion with SUMO protein. The SUMO-tagged mutant proteins were then dialyzed into water,  
62 
 
  
Figure 24: RP-HPLC chromatograms and MALDI-TOF spectra of R0V peptide (A) and the 
double mutant peptide (B). 
 
cleaved by Ulp1 protease, and the mutant peptides were purified by RP-HPLC. The R0V and the 
double mutant peptide were both soluble in the solution, and their presence was confirmed by 
MALDI-TOF (Figure 24). In the mass spec, we observed species that were 22 g/mol greater than 
the MW of each peptide, suggesting that a sodium ion can be associated with these peptides. The 
SUMO-tagged L-1V peptide had poor solubility in water; thus, the peptide could not be purified 
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by RP-HPLC. Nevertheless, MALDI-TOF confirmed that the L-1V peptide was in the peptide 
cleavage solution. Altogether, these results indicate that the mutant peptides are expressed 
properly with the SUMO protein. 
As discussed above, the isolated non-cognate KRAA peptide had limited solubility in the 
NMR buffer likely because it had less charged residues than other peptides. For these mutant 
peptides, we mainly mutated an arginine (charged amino acid) into a hydrophobic residue; thus, 
these peptides might also have limited solubility in NMR buffer. Together with the fact the L-1V 
peptide was not able to be purified by HPLC, the 10xHis-SUMO tag was left intact for all mutant 
peptides. PDZ domain-containing proteins recognize only the C-terminal residues of a target 
protein, so the presence of N-terminal SUMO would not be expected to interfere with 
protein/peptide recognition. Moreover, as discussed above, we previously performed the titration 
of the SUMO-tagged cognate peptide as a control experiment, and confirmed that the presence of 
SUMO did not significantly change the CSP data. After nickel affinity chromatography, the 
SUMO-tagged mutant peptide proteins were purified by FPLC-SEC in the NMR buffer of a pH 
7.0 (Figure 25). Based on its MW, the SUMO-tagged peptide was expected to elute in the 78 mL 
fraction. However, the SUMO-tagged peptide was eluted in the 70 mL fraction. The elution at 
the smaller volume fraction can possibly be due to the presence of the peptide. Fractions that 
contained the protein were concentrated, and titrated into 15N-AF6_PDZ.  
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Figure 25: FPLC-SEC chromatogram of SUMO-fused L-1V peptide protein in NMR buffer at a 
pH of 7.0.  
 
 
Binding interactions of the R0V peptide with AF6_PDZ 
1H-15N-HSQC NMR titration. The SUMO-tagged R0V peptide was titrated into free AF6_PDZ 
to a two-fold molar excess at the following increments: 0.5, 1, and 2 (Figure 26). Similar to the 
cognate peptide, the majority of peaks experienced fast chemical exchange. As observed in the 
cognate peptide, Gly16 reappeared, while Leu19 and Ile21 disappeared in the presence of the 
peptide. In addition, Asn15 reappeared at the last titration point. These observations suggest the 
same behavior as the cognate peptide, in which these peaks are in intermediate exchange regime. 
Since Asp55, Gln14, and Val39 were not observed in the free protein spectrum and the titration 
experiment was performed with large increments of the peptide addition, we were not able to 
track these peaks during the course of the titration.   
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Figure 26: 1H-15N-HSQC NMR titration of R0V mutant peptide into 500 µM AF6_PDZ in 
NMR buffer at pH of 7.0 (50 mM Potassium Phosphate, 1 mM EDTA) at 25 °C. 
 
CSPs data of the R0V mutant peptide and the cognate peptide. Previous research showed class I 
and II ligand binding with a similar binding mode.52 In this study, the cognate peptide is a Class I 
ligand and the R0V mutant peptide is a Class II ligand. Overall, the residues that experienced 
significant chemical shift changes are similar in both classes, indicating the peptides bind at the 
same region (Figure 27 and 28). These residues are primarily located in the binding pocket 
formed by βB and αB of the AF6_PDZ. Several residues in βC, αA, and various loop regions are 
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significantly perturbed, possibly due to secondary effect when the peptide ligand is present.  
Residues at the βB-βC loop had small chemical shift changes, indicating that they do not 
participate in the binding interaction, as observed by others before.55 
  
 
 
 
Figure 27: Surface representation of available structure (2AIN55) mapped with CSP data of the 
cognate peptide (A) and the R0V mutant peptide titration (B). Residues that have minor chemical 
shift changes are yellow (0.07 ppm < CSP < 0.100 ppm). Residues that have significant chemical 
shift changes are orange (0.100 pm < CSP < 0.200 ppm) and red (CSP > 0.200 ppm). White: 
CSP data were not available due to the re- or disappearance of peaks. 
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Figure 28: Comparison plot of the protein CSP data from the cognate peptide (red) and the R0V 
mutant peptide titration (green). Chemical shift changes that are above 0.1 ppm are significant. 
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The Gly-Met-Gly-Leu (Gly16-Met17-Gly18-Leu19) loop region that is located in the N-
terminus of βB has been referred to as the carboxylate binding loop, and it is a conserved 
sequence in PDZ domains in term of hydrophobicity.33 These residues play an important role in 
the recognition of the C-terminus of the peptide ligand by maintaining a hydrophobic pocket to 
stabilize the side chain of a valine residue at P0 of the ligand.
33 Out of these four residues, we 
were able to obtain the CSP for Gly16 and Gly18 for both cognate and R0V peptides (Met17 
were not observed in the free protein, and Leu19 disappeared upon the addition of peptide). 
Gly16 has minor chemical shift changes, while Gly18 experiences the most significant chemical 
shift changes, among all residues of AF6_PDZ. This results suggests that the peptide induces 
significant changes in the chemical environment of Gly18, supporting the crucial role of Gly18 
in the binding interaction in both peptides that we studied.  
Although the two class ligands bind with AF6_PDZ in a similar binding mode, there are 
residues that experience greater magnitude of chemical shift changes in one class versus the 
other (Figure 29, Appendix 2). For the cognate peptide (Class I ligand), Ser20, Val22, Ala23, 
Gly54, Gln70, Glu71, Ala73, Ser81, and Gln91 have greater perturbation compared to the R0V 
peptide. Three residues are located in various loop regions, such as Gly54, Ser81, and Gln91, 
while the other residues are mainly located in βB strand and the N-terminus of αB helix. In case 
of the R0V mutant peptide, there are less residues observed to have greater CSP values than in 
the cognate peptide titration. These residues are Gly18, Ala45, Gly67, Ala74, and Met77. The 
two glycine residues are in flexible loop regions, Ala45 is located in αA helix, and the other two 
residues are located near the C-terminus of αB helix. Together, these observation indicates that 
despite of the similarity of significant perturbed residues, the chemical environment of these 
protein residues in the presence of the peptide may be different in two class binding modes.   
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Figure 29: Ribbon representation of AF6_PDZ (grey) bound with Class I ligand55 (yellow) and 
Class II ligand56 (cyan). Note that the representation is built upon previously solved structure of 
Class I ligand (Bcr) and Class II ligand (nectin), thus the peptide sequences presented here are 
not peptide sequences that were studied in this project. CSP differences between the cognate and 
R0V mutant peptide titration that are greater than 0.05 ppm are considered significant and 
marked in red in the specific class models, accordingly.  
 
Dissociation constant KD. To estimate the binding affinity of the R0V mutant peptide (Class II 
ligand) with AF6_PDZ, CSP data was used. Previous research has shown that AF6_PDZ binds to 
Class II ligand with tighter affinity, due to more interactions between the peptide and the protein, 
and the reported KD for the binding interaction with nectin-3 are 17.8 µM and.56 The estimated 
KD for the R0V peptide is averaged at 26.4 µM with standard deviation of 3.9 µM (Table 10, 
Figure 30). This Kd was close to the reported KD. However, since only three data points were 
used to fit and extrapolate the KD, the estimated KD can only be interpreted as an approximate 
affinity range of the R0V peptide rather than the true KD. Based on this estimated KD, ITC would 
be a better technique to measure and provide a reliable KD. Because of time constraints, we were 
not able to obtain the KD value, though this would be experimentally feasible in the future. 
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Furthermore, by using the SUMO-fused peptide proteins, the problem with heat production from 
buffer mismatch can be easily avoided, due to the fact that these proteins can be dialyzed into the 
same buffer of AF6_PDZ. 
 
 
Table 10: Estimated KD of the R0V peptide binding interaction from various residues that had 
significant chemical shift changes. 
 
 
Figure 30: Non-linear regression analysis to estimate KD of the R0V peptide binding interaction.  
 
Shifted motif peptides 
Shifted-motif mutant peptides (L-1V and double mutant) were titrated into the AF6_PDZ in the 
NMR buffer at a pH of 7.0. These mutant peptides are Class I shifted motif ligands because they 
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have the motif x-Φ-x-Φ-COOH with an additional residue at the extreme C-terminus. The 
titration experiments for both mutants were stopped at the 0.5 molar ratio due to the fact that the 
titration spectra were identical to the free protein spectrum (Figure 31). There are no chemical 
shift changes observed. Under the assumption that less than 5 % of protein bound to the 
peptide54,71, the lower limit of KD of binding interaction between AF6_PDZ and shifted motif 
peptide is estimated at 4.1 mM. This result indicates that the Class I shifted motif ligand does not 
bind to the AF6_PDZ within the physiological range. 
 
Figure 31: 1H-15N-HSQC NMR titration of shifted motif mutant peptide into 500 µM AF6_PDZ 
in NMR buffer at pH of 7.0 (50 mM Potassium Phosphate, 1 mM EDTA) at 25 °C.  
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V. Discussion 
Crucial role of amino acid at the P0 of the peptide ligand  
PDZ domains have been divided into three main classes based on the nature of the first 
residue of its αB helix (αB:1) and the amino acid in the third position upstream of the C-terminal 
residue of the ligand (P-2). The AF6_PDZ was first classified as Class II PDZ domain because it 
has a glutamine residue located the first residue of αB which allows the protein to interact with 
the peptide that has hydrophobic amino acid at the P-2.
48 It was later discovered that the 
AF6_PDZ also recognizes Class I and Class III ligand.31,34 Previously, an array screening of 
biological peptides was performed to establish the specificity profile of AF6_PDZ, specifically 
(π/E)-(Φ/T/S)-x-ΨCOOH.52 However, within the top 100 binding sequences from this array, there 
are several peptide sequences that deviate from the specificity profile.52 We hypothesized that the 
binding interface of AF6_PDZ would have to be plastic and allow AF6_PDZ to make 
accommodation for the deviated residues of the non-cognate peptides. Hence, the binding 
interactions between AF6_PDZ and these peptides were studied to elucidate the binding mode 
that the non-cognate peptides employed, and thereby highlight the important interactions that are 
crucial to promote binding. EPA8 (MENGSLDTFLRCOOH) and KRAA (ACLLSAARLVPCOOH) 
peptides were selected for this study. For both peptides, there are only five residues of the 
AF6_PDZ that have significant chemical shift changes upon peptide titration, indicating that the 
peptides only modestly interact with the AF6_PDZ. Nevertheless, these binding interactions are 
likely not relevant under physiological condition. Furthermore, the KRAA peptide follows the 
shifted motif. As we will discuss later that the shifted motif is not likely relevant for AF6_PDZ, 
the KRAA peptide actually has deviated residue at P0 and P-3 (ACLLSAARLVPCOOH). The 
EPA8 peptide has only one deviated residue at the P0, in which it has a charged residue instead 
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of aliphatic amino acid, while the KRAA peptide has a proline residue at P0. From these 
experiments, we conclude that AF6_PDZ cannot make accommodation for a peptide with a 
deviated residue at P0 of the peptide, and thereby cannot recognize the peptide. This observation 
highlights the important role of the amino acid at the P0 of peptide in binding interaction with 
AF6_PDZ, and further suggests that an arginine or a proline amino acid are likely not preferable 
at the P0 of the peptide.  
Since the binding interaction was not observed in non-cognate peptides, we used a 
knowledge-based approach to introduce mutations into a non-cognate peptide (EPA8) to restore 
binding and thereby elucidate important interactions in promoting binding. Based on the repeated 
occurrence of a valine at the extreme C-terminus of many biological ligands of AF6_PDZ (Table 
2), we mutated the P0 arginine of peptide EPA8 to a valine residue. When studied by 
1H-15N-
HSQC NMR titration, significant chemical shift changes for AF6_PDZ residues occurred upon 
peptide titration, indicating that this designed mutant peptide bound to AF6_PDZ. This 
experiment highlights the important role of valine in promoting binding interaction between a 
peptide ligand and AF6_PDZ. An available structure illustrates that the side chain of valine is 
positioned into the hydrophobic pocket that is formed by Met17, Leu19, Ile21, and Met77.55 Due 
to its hydrophobicity and small side chain, a valine residue helps target the peptide ligand to the 
binding pocket by forming hydrophobic interactions with residues located at the hydrophobic 
binding pocket. Once valine is positioned into the pocket, the carboxyl terminal of the peptide is 
able to form hydrogen bonds with the amino groups of Gly18 and Leu19 of AF6_PDZ. Other 
interactions are consequently formed between residues located at the N-terminal of peptide and 
residues located in the αB and βB strands of the protein. Altogether, a valine residue restores 
binding by initiating hydrophobic and hydrogen-bond interactions with the protein. 
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AF6_PDZ binding interactions with Class I and II ligands  
The cognate peptide in this study is a Class I ligand, while the R0V mutant peptide is a 
Class II ligand. The KD for the binding interactions with AF6_PDZ are estimated by NMR (154 
µM and 26.4 µM, respectively), and in agreement with what others have previously reported.56 
The CSP data of these two peptides titrations have a similar pattern, confirming that these two 
class peptides bind AF6_PDZ using a similar surface, as suggested by others before.52 The 
carboxylate binding loop (Gly16-Met17-Gly18-Leu19) has been known to play an important role 
in recognition of the C-terminus of the peptide ligand.33 In both ligands, Gly18 is significantly 
perturbed as compared to all other residues, confirming its critical role in binding interaction at 
the pocket. Furthermore, similar to what others reported previously, residues that have 
significant chemical shift perturbations are located at αA, αB, βB, and βC.33 Because the peptide 
ligands are known to insert into the binding groove formed by αB and βB of AF6_PDZ, the 
chemical shift changes at αB and βB are expected. As a consequence of peptide insertion, βC and 
αA must undergo secondary changes since they are located at the proximal site of βB, and 
thereby arise chemical shift changes of several residues in these regions. Residues at the βB-βC 
loop had small chemical shift changes, confirming that they do not participate in the binding 
interaction, as has been observed before.33,35   
Despite of the similarity in CSP trend in both class peptides, there are several residues 
that have a greater CSP magnitude in one class but not in the other, and these differences may 
give us an insight in how these peptides interact with AF6_PDZ. Available structures of 
AF6_PDZ bound with Bcr (Class I ligand) and with nectin-3 (Class II ligand) are used to analyze 
these differences.55,56 We observed that Ala74 and Met77 undergo a larger chemical shift 
changes in the R0V peptide (Class II) titration as compared to the cognate peptide one. As we 
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map these residues onto the complex structure of AF6_PDZ with nectin-3, Ala74 and Met77 are 
located proximal to the hydrophobic residue at the P-2 of the peptide (a tryptophan in nectin-3, a 
phenylalanine in the R0V peptide) (Figure 29B). A phenylalanine is an aromatic residue, in 
which the delocalized electrons from its conjugated system can generate a second magnetic field 
and thereby influence the chemical shift changes of neighboring protein residues.73 Therefore, 
the ring current effect from the phenylalanine probably causes the CSP of Ala74 and Met77 
changes in the R0V peptide titration to be greater than their CSP values in the presence of the 
cognate peptide. Other residues, such as Gly18, Ala45, and Gly67, also provide higher chemical 
shift changes in the R0V peptide titration. However, since these residues are located away from 
the binding groove, and the two glycine residues belong to flexible loop regions, their chemical 
shift changes are likely to be secondary effect as a consequence for the R0V peptide insertion. 
Thus, we suggest that the presence of phenylalanine at the P-2 of the R0V peptide influences the 
chemical shift changes of the proximal protein residues by imposing the ring current effect. 
Comparing to the R0V peptide titration, the cognate peptide (Class I ligand) titration 
gives rise to more residues that have the significant higher CSP values (Ser20, Val22, Ala23, 
Gly54, Gln70, Glu71, Ser81, and Gln91). Gly54, Ser81 and Gln91 are located away from the 
binding site, suggesting their changes are possibly due to the modest structural rearrangements in 
the presence of the cognate peptide. Other residues are located predominantly in the βB-strand 
and the N-terminal αB-helix. An available structure of AF6_PDZ bound with Bcr (Class I 
ligand) reveals that the amino acid at the P-4 of the peptide interact with Val22 of AF6_PDZ, 
while in the Class II ligand binding mode (nectin-3), researchers have found that only the last 
three amino acids of the peptide, up to the P-2, contribute in the binding interaction.
55,56 In light 
of this, it is possible that the cognate peptide has more interactions with the protein than the R0V 
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peptide, which in turn introducing more changes in the chemical environments of Val22 and 
Ala23. Furthermore, in the Class II ligand binding mode, to accommodate the bulky residue at  
P-2 of the peptide, αB has been found to be displaced 2.5 Å away relative to αB in the Class I 
binding mode to widen the binding groove.56 Hence, the presence of the cognate peptide in a 
narrow binding groove likely induces more changes in the chemical environments of residue 
located in βB and the N-terminus of αB, and thereby arise the greater CSP values, as we compare 
with the R0V mutant peptide.  
 
Shifted motif peptides  
Upon confirming the crucial role of valine, we investigated the shifted motif ligand 
recognition of AF6_PDZ. For both of the shifted-motif peptides that we designed, no chemical 
shift changes were observed in the protein upon addition of the ligand, indicating that the 
AF6_PDZ does not bind these shifted motif ligands. The lower limit of KD is estimated to be 4.1 
mM, with the assumption that less than 5% of protein was bound to peptide at the highest 
concentrations used.57,71 This is consistent with previous research reporting a titration of AG22 (a 
Class I shifted motif ligand) into 100 µM AF6_PDZ and minor chemical shift changes were 
observed.52 Under the high concentration of peptide used in previous research, these minor 
chemical shift changes can be due to nonspecific interaction rather than peptide-protein 
interaction. Furthermore, Boisguerin notes that the KD of the binding interaction of AF6_PDZ 
with AG22 is estimated at around 78.9 µM to 287.3 µM by SPR.52 With this estimated KD and 
our NMR condition, there would be at least 27.8 % (135 µM) protein bound to the peptide, and 
this would be able to observe in our titration spectrum. The result suggests that the measured KD 
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from SPR is inaccurate and not reflected the actual KD. Since we observe no chemical shift 
changes and the lower limit of KD is estimated at be 4.1 mM, we conclude that AF6_PDZ does 
not recognize shifted motif ligands.  
Furthermore, the shifted motif peptide is not biologically relevant in AF6_PDZ binding 
system. Although Boisguerin reported that an additional residue at P+1 is predicted to weaken the 
binding affinity by 10-15 fold, based on our experiment, we suggest that the binding affinity is 
altered by more than 15 fold. AF6_PDZ binds Class I and Class II ligands with weak binding 
affinity (20 µM – 100 µM). Taking in consideration of more than 15-fold change in KD, these 
shifted motif ligands are probably not relevant for AF6_PDZ under the physiological condition. 
The system of shifted motif ligands would be more relevant to tight binding interaction, in which 
upon introduction of additional residue, the reduced KD of binding interaction is still within the 
physiological range. Therefore, we conclude that proteins containing shifted motif peptide are 
likely not physiological binding partners of AF6_PDZ. 
Moreover, as compared to ERBIN_PDZ, AF6_PDZ has an additional α-helix, which may 
impose structural constraint and inhibit AF6_PDZ to recognize the shifted motif peptide. Unlike 
AF6_PDZ, ERBIN_PDZ was shown to bind the shifted motif peptide AG22 with a reproducible 
KD of 105.4 µM.52 Hence, the shifted motif peptide was proposed to be a potential binding 
partner of PDZ domain. Comparison of the structures of ERBIN_PDZ and AF6_PDZ reveals 
that AF6 has an additional α-helix (αA) in between βC and βD strands (PDB: 1T2M33), where 
ERBIN_PDZ has an extended loop in this region (PDB: 2H3L74). We hypothesize that the 
second α-helices of AF6_PDZ may impose structural constraints, which in turn inhibiting 
conformational changes that are necessary to accommodate the shifted motif peptide. Future 
experiments need to be done to further confirm this hypothesis, such as collecting the CSP data 
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from a titration of AG22 peptide into ERBIN_PDZ and obtaining their complex structure to 
elucidate the structural components that are important in the shifted motif binding mode. Hence, 
these structural components can be used to rationalize why AF6_PDZ does not recognize the 
shifted-motif peptide. 
The shifted motif peptides do not bind AF6_PDZ; however, within the top 100 binding 
sequences, there are 10 sequences that follow this motif, raising question about the validity of 
this list of binding sequences. We suggest that the reported list does not truly reflect all 
biological binding partners of AF6_PDZ that have KD of the binding interaction at the mid-
micromolar range. From the list, the peptide sequence of Bcr is reported which has been shown 
by many others that it binds AF6_PDZ with KD of approximately 100 µM.31,33,55 However, many 
other biological binders, such as neurexin, nectin-3, and Jagged-1, are not reported in the list, 
even though they bind AF6_PDZ with KD of approximately 10 – 20 µM.32,33 Therefore, in future 
experiments, the top 100 binding sequences need to be used with precautions.  
 
Future directions 
Peptide EPA8 had a phenylalanine at P-2 and an arginine at P0. Upon mutating the 
arginine residue into a valine residue, the binding was restored. This highlights that a valine 
residue at the C-terminus of the peptide is crucial to promote binding. Due to the phenylalanine 
at P-2, the mutant peptide became a Class II ligand upon the valine mutation at P0. Based on the 
specificity profile for AF6_PDZ, residues at P-2 are either hydrophobic residues, serine, or 
threonine. Therefore, we are only able to conclude the role of valine in tailoring the peptide to 
the binding groove. We are interested in the role of valine in peptides that do not have the 
79 
 
preferable residue at P-2. In future experiments, unfavorable mutations can be introduced at P-2 of 
peptide ligand to study whether the binding interaction is still able to occur. Such experiments 
will address whether the valine alone is sufficient for peptide binding, even when other peptide 
residues do not follow the expected profile. From the top 100 binding sequences, we find five 
potential sequences for future study.52 These peptide sequences have a valine at P0 and 
unfavorable residue at P-2, in which three of these sequences have a charged residue (an arginine) 
at P-2 while the other sequences have a polar residue other than serine and threonine at P-2 (an 
asparagine and a glutamine).52 Interestingly, previous researchers solved the crystal structure of 
the PDZ domain of Calcium/Calmodulin-dependent serine protein kinase (CASK) complex with 
a peptide that has an arginine at P-2 (YREFCOOH).
74 The structure reveals that the arginine of the 
peptide can be accommodated by turning its charged group to the solvent and allowing its 
hydrophobic carbon chain to interact with the protein.74 This accommodation is accomplished by 
the hydrogen bond formation between the side chain of the arginine residue of the peptide and 
the glutamine at the fourth position of αB helix (αB:4) of the protein.74 For AF6_PDZ, a 
glutamine residue is found at the αB:1, while a valine is located at the αB:4. We are interested to 
see whether the glutamine residue of AF6_PDZ can establish a hydrogen bond with the arginine 
of the peptide. In light of that, we would be able to assess the ability of AF6_PDZ to recognize a 
peptide with arginine at P-2, and possibly elucidate the binding interactions that takes place to 
better understand the specificity of AF6_PDZ. 
 Finally, the ability of AF6_PDZ to recognize a Class III ligand (c-Src: GENLCOOH) has 
been recently discovered.34 There is no solved structure for the complex of AF6_PDZ bound to 
c-Src. Future research can be done to obtain the structure of the complex and the KD of the 
binding interaction. The structure will aid in identifying other intermolecular forces that occur at 
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the binding pocket, as well as structural components that allow AF6_PDZ to recognize a Class 
III ligand. Moreover, the peptide sequence of c-Src can also be used in amino acid substitution 
analysis to modify the previous specificity profile of AF6_PDZ. Altogether, the knowledge will 
aid scientists in designing therapeutic drug to target the AF6_PDZ, and identifying other 
unknown biological binding partner of AF6_PDZ. 
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VI. Conclusion 
 The work presented here has contributed to elucidating important intermolecular 
interactions at the binding pocket that promotes binding between a rage of chemically distinct 
peptide ligands and AF6_PDZ. First, we studied the binding interaction between non-cognate 
peptides with AF6_PDZ. These peptides only weakly interact with the protein, if at all. We 
then introduced a valine mutation at the P0 of a non-cognate peptide and the binding was 
restored. This highlights the critical role of a valine residue at the P0 in tailoring the peptide to 
the binding pocket and initiating hydrophobic and hydrogen bond interaction with AF6_PDZ. 
Lastly, we studied the shifted motif ligands and were able to conclude that AF6_PDZ does not 
recognize these ligands, and the shifted motif system is likely not relevant in the physiological 
condition. Examination of the structures allows us to hypothesize that the αA helix of 
AF6_PDZ possibly imposes some structural constraint and inhibits the recognition of shifted 
motif peptide. In summary, this project gives a better understanding of the binding interaction 
between AF6_PDZ and various peptides, and these preliminary data can be used to support 
future experiments. 
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VIII. Appendices: 
Position Residue 1H (ppm) 15N (ppm)  Position Residue 1H (ppm) 15N (ppm) 
2 Lys 8.42 124.04  28 Gly 8.72 110.13 
3 Glu 8.43 124.06  29 Gln 7.87 117.68 
4 Pro    30 Asp 8.48 119.04 
5 Glu 8.46 122.9  31 Lys 7.66 118.76 
6 Ile 8.22 125.4  32 Leu 8.33 122.12 
7 Ile 9.1 123.46  33 Gly 8.68 110.57 
8 Thr 8.42 118.42  34 Ile 8.75 119.57 
9 Val 9.24 126.55  35 Tyr 9.22 124.18 
10 Thr 7.97 123.43  36 Val 8.95 119.82 
11 Leu 9.1 125.99  37 Lys 9.56 134.01 
12 Lys 8.59 123.9  38 Ser 7.43 109.57 
13 Lys 8.48 123.11  39 Val 8.46 121.09 
14 Gln 7.99 121.07  40 Val 7.86 127.15 
15 Asn 8.74 121.14  41 Lys 9.07 133.17 
16 Gly 8.09 106.82  42 Gly 10.64 117.44 
17 Met    43 Gly 7.78 106.87 
18 Gly 8.64 105.96  44 Ala 8.62 118.94 
19 Leu 7.76 118.9  45 Ala 7.79 118.44 
20 Ser 8.5 117.71  46 Asp 8.93 123.39 
21 Ile 8.65 117.46  47 Val 8.27 116.89 
22 Val 8.98 117.05  48 Asp 7.63 118.77 
23 Ala 8.27 127.06  49 Gly 7.38 102.99 
24 Ala 9.38 125.48  50 Arg 7.87 118.57 
25 Lys 8.53 120.94  51 Leu 8.47 119.67 
26 Gly 8.44 112.36  52 Ala 8.92 124.31 
27 Ala 8.41 123.97  53 Ala 8.46 121.49 
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54 Gly 9.08 111.89  74 Ala 8.55 119.26 
55 Asp 8.05 121.46  75 Glu 7.6 119.31 
56 Gln 8.62 121.41  76 Leu 7.66 119.56 
57 Leu 8.92 126.39  77 Met 7.98 114.86 
58 Leu 9.11 124.2  78 Thr 7.99 114.75 
59 Ser 7.64 111.57  79 Arg 7.38 123.48 
60 Val 8.6 117.48  80 Thr 7.45 110.68 
61 Asp 9.98 130.76  81 Ser 9.02 118.25 
62 Gly 8.81 102.6  82 Ser 8.18 113.79 
63 Arg 8.16 122.22  83 Val 7.51 119.53 
64 Ser 8.56 118.1  84 Val 8.97 126.95 
65 Leu 8.02 124.79  85 Thr 8.86 122.9 
66 Val 7.93 122.68  86 Leu 9.57 130.16 
67 Gly 8.62 116.21  87 Glu 7.46 121.54 
68 Leu 7.86 121.54  88 Val  9.26 125.79 
69 Ser 7.74 112.57  89 Ala 9.15 128.17 
70 Gln 8.95 120.3  90 Lys 8.9 125.55 
71 Glu 8.86 117.06  91 Gln 8.75 122.64 
72 Arg 7.7 120.58  92 Gly 8.53 111.27 
73 Ala 8.52 122.51  93 Ala 7.93 129.47 
  
Appendix 1: 1H-15N HSQC backbone assignments of AF6_PDZ at 25 °C (buffer: 50 potassium 
phosphate (pH of 5.8) and 1 mM EDTA). Hydrogen and nitrogen chemical shifts for each 
residue are listed, except Pro4 and Met17. 
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Appendix 2: Difference plot of CSP of the cognate and R0V mutant peptide titration. The 
difference was found by subtracting the CSP value of the R0V peptide from the CSP value of the 
cognate peptide. CSP differences are considered significant when the difference is greater than 
0.05 ppm. 
